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Abstract 
Cardiac pathology related to stress and life-style is a major cause of death in humans. It is also 
an emerging problem for the salmon aquaculture industry. This industry produces semi-
domesticated fish in very intensive rearing regimes, and the underlying causes for heart 
pathology are largely unknown. A recent study showed that the “stress hormone” cortisol 
induces heart growth in rainbow trout (Oncorhynchus mykiss). Furthermore, increased heart size 
in fish is associated with up-regulation of several heart disease markers well-known from human 
cardiology. In the current study, we first aimed at determining the time-course for cortisol-
induced heart growth. To this end, we measured relative ventricle size in rainbow trout after 2, 7 
and 21 days of non-invasive cortisol administration. This experiment revealed a steep growth 
phase of the hearts around 21 days of cortisol treatment, with indications of marked growth even 
earlier. Cortisol mediates its effects on the heart through cardiac mineralocorticoid (MR) and 
glucocorticoid receptors (GRs). In order to investigate receptor-specific effects of cortisol on 
heart phenotype and cardiac markers, rainbow trout were administered feed enriched with 
cortisol alone or in combination with specific cortisol receptor antagonists for 21 days. In the 
latter experiment, relative ventricle weight was increased by 20% in cortisol-treated fish 
compared to controls, an increase which was not blocked by any of the antagonists. Heart 
growth was accompanied by increased mRNA levels of the hypertrophy markers VMHC and 
SMLC2. Combined with decreased levels of the proliferation marker, PCNA, this indicates that 
the hearts were growing mainly through hypertrophy. There was a strong tendency towards 
higher PCNA mRNA levels in fish treated with cortisol in combination with the GR antagonist 
mifepristone. Similarly, markers of collagen synthesis COL1α1 and COL1α2 mRNAs were 
significantly decreased by the cortisol treatment, a decrease which was partially blocked by the 
GR antagonist. This indicates that the suppressing effect of cortisol on COL1α1 and COL1α2, 
and likely PCNA as well, is mediated through the cardiac GR. No consequence of blocking the 
cardiac MR by use of spironolactone was seen. However, quite unexpectedly, cortisol 
suppressed feed intake by an apparent inhibition of the swallowing reflex, and this effect was 
abolished by the GR antagonist. This observation can explain frequent observations of low feed 
intake in stressed fish and may have important implications for the aquaculture industry.  In 
conclusion, cortisol administration significantly induces heart growth after 21 days of cortisol 
treatment. The involvement of the two cortisol receptor types in inducing cardiac remodeling in 
salmonids remains to be clarified. 
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1 INTRODUCTION 
The global aquaculture industry produces millions of tons of salmonid fishes yearly and 
mortality associated with cardiac dysfunction and disease is a growing problem. The lifestyle 
of domestic salmonids differs considerably from wild salmonids in that they are less active 
and often overfed. This is reflected in some aspects of their cardiac morphology and 
physiology (Gamperl and Farrell, 2004). Whereas the ventricle of wild salmonids has a 
pyramidal (triangular) shape, the ventricle of domestic salmonids tends to be more rounded 
with fat deposits, atherosclerosis and malformations (Poppe et al., 2003; Gamperl and Farrell, 
2004). The underlying causes of the pathological cardiac remodeling in domestic salmonids 
are however poorly investigated and largely unknown.  
Wild salmonids are athletic and can migrate thousands of kilometers during their 
lifespan. This active lifestyle is reflected in the structure of their ventricle which has a well-
developed outer compact myocardium, a characteristic feature of athletic fish species (Farrell 
and Jones, 1992). The salmonid ventricle consists of an outer layer of circumferentially 
arranged compact myocardium encasing an inner layer of spongy myocardium (Pieperhoff et 
al., 2009) (Figure 1). Coronary blood vessels supply the compact myocardium with 
oxygenated blood from the gills while the spongy myocardium is supplied with oxygen 
directly from the venous blood returning to the heart.  
 
Figure 1 20 µm cryosections through the rainbow trout ventricle stained with WGA (wheat germ 
agglutinin) conjugated to Alexa fluor 488. Imaged with Zeiss LSM 710 confocal microscope.  
To the left: the outer compact myocardium of circumferentially arranged cardiomycytes and the inner spongy 
myocardium. To the right: 60x magnification of individual cardiomyocytes in spongy myocardium lying 
longitudinally and transversely. Photo: Michael Frisk   
Perhaps as a result of the high functional demands associated with its natural lifestyle, 
the salmonid heart demonstrates a remarkable degree of plasticity. This plasticity is, at least 
partly, due to the ability of the two compartments of the ventricle to grow both through 
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hypertrophy (growth of single cardiomyocytes) and hyperplasia (proliferation of 
cardiomyocytes) (Gamperl and Farrell, 2004). 
The heart morphology within one species can vary considerably depending on 
environmental and physical demands (Gamperl and Farrell, 2004). For example, cold 
acclimation induces cardiac hypertrophy in salmonids, a remodeling mechanism which 
enables them to compensate for a cold-temperature-induced decrease in contractility of the 
heart (Vornanen et al., 2005). Also, among different populations of sockey salmon, it was 
shown that heart size and morphology is determined by what historical environmental 
conditions the fish have encountered while migrating (Eliason et al., 2011).  
This high potential for plastic changes may however also involve an increased risk of 
pathological cardiac remodeling. This seems to have serious consequences for farmed 
salmonids with their inactive lifestyle and overfeeding. Abnormally shaped hearts are likely to 
be a widespread phenomenon in fish farming (Poppe et al., 2003). Moreover, domestic 
salmonids have decreased swimming capacity compared to wild fish (Duthie, 1987; 
McDonald et al., 1998), which suggests reduced cardiac function. Interestingly, when farmed 
and wild salmonids were raised under identical conditions they did not differ in either 
swimming performance or cardiac function (Dunmall and Schreer, 2003), indicating that the 
underlying causes are not genetic.  
Fish suffering from cardiac pathologies are highly sensitive to stress. Their cardiac 
capacity is sufficient to handle the limited physical demands within the cages, but they are 
unable to handle stress factors that are a recurring part of aquaculture operations (Poppe et al., 
2003). Episodes of sudden death during crowding, grading and transportation are common 
and are found to be due to cardiac rupture or other conditions of cardiac or vascular 
dysfunction (Brocklebank and Raverty, 2002; Tørud et al., 2004; Poppe et al., 2007). 
Salmonids are subjected to a number of stressors in commercial fish rearing, some of which 
are of chronic nature (such as crowding, confinement to relatively small volumes of water, 
and social hierarchies) (Pickering and Stewart, 1984; Cubitt et al., 2008).   
An elevation in plasma cortisol is a central component of the physiological response to 
stress. Chronic stress is known to have long-term detrimental effects in fish and these are 
mainly mediated by cortisol (Barton et al., 1987), which is the major steroid stress hormone in 
both fish and humans. Cortisol responsiveness to stress is a highly heritable genetic trait and 
in humans, such high cortisol responsiveness is associated with increased risk of 
cardiovascular mortality (Pedersen and Denollet, 2003). Oral intake of glucocorticoids 
increases the risk of developing heart disease (Souverein et al., 2004). In rodents, 15 days of 
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treatment with the synthetic glucocorticoid dexamethasone induces heart growth and fibrosis 
(Roy et al., 2009) and cortisol application has been shown to induce hypertrophy in 
mammalian fetal hearts (Reini et al., 2008). Furthermore, cortisol induces hypertrophy in 
vitro, which indicates a direct effect of cortisol on the cardiomyocytes (Nichols et al., 1984). 
The direct effects of cortisol on the mammalian heart are far from understood, in particular 
the underlying molecular mechanisms. 
Many important aspects of organ function and physiology are conserved between fish 
and mammals, and teleost fishes are emerging as alternatives to small mammals as models in 
biomedical research (Epstein and Epstein, 2005). Recently, a link between high cortisol 
responsiveness and cardiac pathology was found also in fish (Johansen et al., 2011) and long-
term administration of cortisol in the feed induces heart growth in rainbow trout (Johansen et 
al., unpublished). This suggests that cortisol might be one of the causes for pathological heart 
conditions also in the fish farming industry. It is thus of interest to study how stress and 
cortisol in particular affects the heart of salmonids. 
Salmonids are often studied because of their economic and ecological importance, but 
they are also important model systems for studying the evolution of the vertebrate 
cardiovascular system and comparative aspects of cardiac physiology (Farrell et al., 1988; 
Pieperhoff et al., 2009). The high degree of plasticity and the large size of salmonids facilitate 
easy investigation of heart phenotype and salmonid fishes are thus good models for 
investigating certain aspects of cardiac remodeling.  
I will in the following review the mechanisms involved in cardiac remodeling, 
including steroid actions on the mammalian heart, before I outline the background and 
specific hypothesis underlying the experiments in this thesis. 
1.1 Cardiac remodeling 
1.1.1 Cellular mechanisms of cardiac remodeling 
Whereas the adult fish heart can grow through both hyperplasia and hypertrophy, 
cardiac growth in adult mammals is mainly restricted to cardiomyocyte hypertrophy 
(Swynghedauw, 1999). The mammalian heart can undergo cardiac hypertrophy as a result of 
exercise or during pregnancy, a heart growth which is generally classified as physiological. 
Although cardiac hypertrophy in mammals is not necessarily pathological, it does represent an 
independent risk factor for adverse cardiac events (Ho et al., 1993; Lloyd-Jones et al., 2002). 
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Myocardial remodeling may occur after a number of pathological heart conditions of which 
the most common are myocardial infarction and chronic hypertension (Swynghedauw, 2006). 
Myocardial remodeling underlies the progressive development of heart failure, a syndrome in 
which the heart is not able to pump out an adequate amount of blood to meet the requirements 
of metabolizing tissues (Braunwald and Bristow, 2000).  
Cardiac remodeling is characterized by myocyte hypertrophy and apoptosis, 
hyperplasia and hypertrophy of nonmuscular cells, alterations to the extracellular matrix and 
to fibroblast function and inflammation (Swynghedauw, 1999). Myocardial hypertrophy is 
characterized by increased protein synthesis and reorganization of the sarcomeres 
(Swynghedauw, 1999) and may also be accompanied by increased vascularization to meet the 
higher metabolic demands of hypertrophic cells and an increased number of cardiac 
fibroblasts causing fibrosis (Barry et al., 2008).  
Fibrosis is the disproportionate accumulation of fibrillar collagen and is defined by an 
increase in myocardial collagen concentration (Weber et al., 1994). Normally, the fibrillar 
collagen network serves an elastic element in the heart but the presence of fibrosis adversely 
enhances myocardial stiffness, generates arrhythmias and impedes systolic ejection 
(Swynghedauw, 1999).  
1.1.2 Molecular mechanisms of cardiac remodeling 
At the molecular level, cardiac remodeling results from re-expression of the fetal gene 
program (i.e genes that are normally expressed only in the developing heart and are repressed 
in the adult myocardium), including switching isoforms of contractile proteins such as myosin 
and actin and induction of natriuretic peptides (Swynghedauw, 1999; Barry et al., 2008).  
Myosin, the primary constituent of the thick filament of the sarcomere, is a protein 
composed of a pair of heavy chains and two different pairs of light chains. Cardiac 
hypertrophy in patients and rodent models is characterized by an increase in expression of the 
β-myosin heavy chain (β-MHC) and a reduction in expression of the α-myosin heavy chain 
(Barry et al., 2008). Re-expression of the embryonic myosin light chain (MLC) and up-
regulation of skeletal alpha-actin (α-actin) and muscle LIM protein (MLP) is also commonly 
found in hypertrophic mammalian hearts (Swynghedauw, 1999; Lim et al., 2001).  Few 
studies have identified molecular markers for pathological cardiac remodeling in fish but 
some markers of cardiomyocyte hypertrophy in mammals seem to be applicable to fish as 
well. During cold-induced hypertrophic growth of the rainbow trout heart,Vornanen et al. 
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(2005) observed an up-regulation of ventricular myosin heavy chain (VMHC) (i.e the fish 
homologue of β-MHC), slow myosin light chain (SMLC2) (i.e the fish homologue of 
embryonic MLC) and muscle LIM protein (MLP).  
Since the fish heart also grows through hyperplasia, cell proliferation may constitute 
an important part of cardiac remodeling in fish. Proliferating cell nuclear antigen (PCNA), an 
auxiliary factor for DNA polymerase δ which is expressed in all the stages of the cell cycle 
except G0 (Köhler et al., 2005), is a commonly used marker of cell proliferation in fish 
(Johansen et al., 2011; Sørensen et al., 2011), birds (Köhler et al., 2005) and mammals (Kurki 
et al., 1988).   
The calcineurin-nuclear factor of activated T-cell (NFAT) pathway is one of the major 
pathways involved in pathological hypertrophy in mammals (Wilkins et al., 2004). In normal 
cardiomyocytes, calcineurin-NFAT signaling is inactive, but in hypertrophic cardiomyocytes, 
NFAT is dephosphorylated by calcineurin and translocates to the nucleus where it activates 
pro-hypertrophic genes such as the regulator of calcineurin 1 (RCAN1) (Lunde, 2012). Since 
RCAN1 is a direct gene target for the NFAT transcription factor an increased expression of 
RCAN1 indicates NFAT-activity. The NFAT transcription factor family is thought to have 
arisen about 500 million years ago and to be found only in the genomes of vertebrates (Wu et 
al., 2007). Johansen et al. (2011) showed for the first time that NFAT activation also occurs in 
the hypertrophic fish heart.  
The natriuretic peptides (NPs) are a family of hormones that affect the cardiovascular 
system through their effects on diuresis, natriuresis, vasorelaxation, aldosterone and renin 
inhibition (Barry et al., 2008). During mammalian embryological development atrial 
natriuretic peptide (ANP) is expressed in the atrium, while B-type natriuretic peptide (BNP) is 
expressed in both the atrium and ventricle but both peptides are absent from the ventricles of 
healthy adults.  They are however re-expressed in the ventricle in response to hypertrophic 
stimuli such as pressure or volume overload (Loretz and Pollina, 2000). Their main function 
in the myocardium is to inhibit the hypertrophic response (Barry et al., 2008) by reducing 
blood pressure and volume (Loretz and Pollina, 2000). ANP and BNP are highly expressed in 
hypertrophic hearts and expression increases with the progression of heart failure (Tota and 
Cerra, 2009), suggesting that at some point they are insufficient in halting this progression. 
The anti-hypertrophic effect of NPs might also be impaired during heart failure (Barry et al., 
2008). Plasma BNP levels are predictive of cardiovascular mortality and heart failure, and 
ANP and BNP are commonly used as markers of heart failure in human cardiology (Gardner, 
2003).  
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Teleost fishes also synthesize the natriuretic peptides ANP and BNP and an additional 
ventricular form called ventricular natriuretic peptide (VNP). The role of natriuretic peptides 
in fish is not as well understood as in mammals. As for mammals, blood volume expansion 
(hypervolemia) resulting in atrial stretch induces NP release. However, hyperosmolarity 
seems to be more potent than hypervolemia in stimulating ANP release (Tota and Cerra, 
2009) and NPs have been suggested to be seawater adapting hormones (Loretz and Pollina, 
2000). The inhibitory mechanisms induced by NPs to protect the heart against overstimulation 
appear to be evolutionarily conserved. The long-term effects of NPs on heart growth and 
remodeling in fish are however not known (Tota and Cerra, 2009). Vornanen et al. (2005) 
found the expression of BNP to be strongly enhanced in the hypertrophic heart of cold-
acclimated rainbow trout.  
In addition to isoform switching of contractile proteins and induction of natriuretic 
peptides, mammalian cardiac hypertrophy is often characterized by increased vascularization 
and fibrosis. Type I collagen is the main constituent of fibrosis. It is also an important 
component of the normal fibrillar collagen network but is then secreted by fibroblasts at a 
very low rate (Swynghedauw, 1999). In fibrosis, collagen synthesis is increased, and the 
genes encoding the chains in type I collagen, called collagen alpha 1(1) (COL1α1) and 
collagen alpha 2(1) (COL1α2), can be used as markers of collagen synthesis and fibrosis. 
Increased vascularization can be detected at the molecular level by enhanced 
expression of genes involved in the process of angiogenesis. Vascular endothelial growth 
factor (VEGF) is a protein that stimulates angiogenesis and can be induced in cells that are 
not receiving enough oxygen. It is a commonly used marker of angiogenesis in fish and 
mammals (Cerra et al., 2004).  
1.2 Corticosteroids and corticosteroid receptors 
Corticosteroids have been found to have both protective and adverse effects on cardiac tissue. 
Corticosteroid receptors are abundantly expressed in the heart of mammals and teleost fish, 
including rainbow trout (Greenwood et al., 2003; Sturm et al., 2005), indicating that 
corticosteroids have the ability to affect the function of this organ. In mammals, 
corticosteroids are produced by the adrenal cortex and are divided into two main groups; 
glucocorticoids and mineralocorticoids. Glucocorticoids were named for their effects on 
glucose metabolism, but they also play important regulatory roles in metabolism, 
development, immune function and the stress response (Sturm et al., 2005). Cortisol is the 
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major glucocorticoid in humans and fish. Mineralocorticoids were named for their well-
known effects on the regulation of sodium and water homeostasis. Aldosterone, which is the 
major mineralocorticoid in mammals, has also been implicated in various cardiac pathologies 
in mammals (Rossier, 2008). 
An important difference between mammalian and teleost corticosteroid secretion is the 
absence of significant production of aldosterone in teleosts (Prunet et al., 2006). Aldosterone 
has only been demonstrated in minute amounts in teleost fishes and appears to be without 
physiological significance (Wendelaar Bonga, 1997). It is the consensus that cortisol acts both 
as a mineralocorticoid and glucocorticoid (Wendelaar Bonga, 1997; Sturm et al., 2005), and 
therefore serves a broader range of functions in teleost fish than in mammals. In addition to its 
glucocorticoid functions which are similar to those in mammals, cortisol is a key hormone in 
sea water adaptation in fish, and has been shown to regulate chloride cell function during 
freshwater adaptation (Sturm et al., 2005). Cortisol is also the major steroid stress hormone in 
fish. As a major component of the stress response in both fish and mammals, cortisol is 
involved in eliciting a set of behavioral and physiological responses that allows the animal to 
compensate for and/or adapt to a stressor (Wendelaar Bonga, 1997). However, in animals that 
are experiencing chronic stress, this response can lose its adaptive value and may become 
dysfunctional. Long-term and abnormally high cortisol levels have been shown to have 
several negative effects including reduced growth rate and suppression of reproduction and 
immune function (Wendelaar Bonga, 1997).  
In fish, cortisol is produced by steroidogenic cells in the interrenal tissue of the head 
kidney (Mommsen et al., 1999). The secretion of cortisol is mainly controlled by the 
hypothalamus-pituitary-interrenal axis (HPI-axis), which is equivalent to the mammalian 
hypothalamic-pituitary-adrenal axis. The endocrine regulation of cortisol in teleost fish is 
complex. Simplified, activation of the HPI-axis, results in the release of corticotrophin-
releasing hormone (CRH) from the hypothalamus which stimulates the secretion of 
adrenocorticotrophin (ACTH) from the pituitary into the circulation. ACTH stimulates the 
production and release of cortisol from the interrenal tissue. Because cortisol is a hydrophobic 
molecule it can easily cross membranes and it is transported in the blood bound to plasma 
proteins. Cortisol inhibits its own production through negative feedback on the HPI-axis.    
The effects of cortisol are mediated through corticosteroid receptors (Prunet et al., 
2006). The sensitivity of a particular tissue to cortisol is dependent on the intracellular 
concentration of receptors and type of receptors present (Mommsen et al., 1999). 
Corticosteroid receptors are expressed in various tissues in fish including the gills, intestine, 
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liver, brain and heart (Greenwood et al., 2003; Sturm et al., 2005).  The two main types of 
corticosteroid receptors in fish are the mineralocorticoid receptor (MR) and the glucocorticoid 
receptor (GR). Whereas one MR and one GR have been demonstrated in mammals, one MR 
and two GR paralogues (GR1 and GR2) have been characterized in rainbow trout (Bury et al., 
2003). In mammals, MR has a higher affinity for cortisol than GR. The rainbow trout MR has 
high homology to the mammalian MR and also displays a higher affinity for cortisol than the 
two GRs (Sturm et al., 2005). Since the two GR paralogues in teleosts have different 
sensitivities to cortisol it has been suggested that these two GR isoforms may have different 
functions (Bury and Sturm, 2007). In trout, GR2 induces transcription at much lower 
concentrations of glucocorticoids than GR1, indicating that GR2 might be transcriptionally 
active at basal cortisol levels whereas GR1 is first active at elevated concentrations such as 
during stressful events. 
Corticosteroid receptors are ligand-inducible transcription factors that, in the absence 
of ligand, reside in the cytosol as large heteromeric complexes with heat shock proteins 
(Prunet et al., 2006). Upon ligand binding, they dissociate from the complex and translocate 
to the cell nucleus where they modulate gene transcription through transactivation and 
transrepression (Datson et al., 2008) In transactivation, corticosteroid receptors form dimers 
(homodimers and heterodimers) that bind to glucocorticoid responsive elements (GREs) in the 
promoter region of primary responsive genes (i.e genes that are under direct control of 
corticosteroids). Subsequently, they recruit cofactors and histone modifying enzymes and the 
expression of the gene is either enhanced (if binding to positive GREs) or inhibited (if binding 
to negative GREs). In transrepression, corticosteroid receptors form monomers that interact 
with other transcription factors activated through other pathways to inhibit gene expression 
(Datson et al., 2008).  
In addition to the effects on primary responsive genes, corticosteroids can exert 
secondary, tertiary and even more downstream effects on gene expression (Datson et al., 
2008). This occurs when the mRNA of a primary responsive gene is translated into protein 
which subsequently modifies the transcription of other genes. The genomic effects of 
corticosteroids are believed to be the main mechanism for corticosteroid action (Datson et al., 
2008; Lee et al., 2012). There are however several recent reports of rapid non-genomic effects 
of corticosteroids which are not mediated by transcriptional regulation but by alternative 
pathways, in several tissues including cardiovascular tissues (Lee et al., 2012). 
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1.3 Cortisol and aldosterone: actions on the mammalian 
heart 
Aldosterone has been implicated in various cardiac pathologies (Rossier, 2008). It acts 
through the mineralocorticoid receptor and can produce deleterious structural changes to 
cardiac tissue by inducing hypertrophy and dysregulation of proliferation and apoptosis, 
which can result in fibrosis and pathological tissue remodeling (Dooley et al., 2011). Research 
using animal models, has shown that the deleterious effects of aldosterone also requires a high 
salt intake which indicates that it is the inappropriate activation of the MR based on changes 
to the electrolyte balance that causes this effect (Rossier, 2008). The MR antagonists 
spironolactone and eplerenone are administered to individuals with severe heart failure 
because of their ability to substantially improve the morbidity and mortality of these patients 
(Pitt et al., 1999; Pitt et al., 2003). 
Cortisol, on the other hand, has been considered to protect cardiac tissue. Cortisol 
circulates in much higher concentrations than aldosterone. In aldosterone target tissues such 
as the kidney and intestine, the enzyme 11β-hydroxysteroid dehydrogenase type 2 (11β-
HSD2) converts cortisol into its inactive metabolite cortisone, thus making the MR available 
for aldosterone (Sturm et al., 2005). This enzyme is however not found in cardiomyocytes and 
since MR binds cortisol with a similarly high affinity as aldosterone, the cardiac MR is 
expected to be constantly occupied by glucocorticoids. However, because mineralocorticoids 
are much more efficient than glucocorticoids at transcriptionally activating the MR, cortisol 
binding would not activate the MR but instead function as an antagonist to aldosterone and 
protect the heart (Rossier, 2008). Recent studies have however revealed that under certain 
conditions, cortisol can mimic the deleterious effects of aldosterone on cardiac tissue 
(Rossier, 2008). Taken together, this research indicates that inappropriate activation of MR is 
harmful for the heart, but the molecular mechanism(s) modulating the activity of the cardiac 
MR and the molecular effectors of mineralocorticoids leading to various cardiac pathologies, 
are not well known (Rossier, 2008).   
1.4 Cortisol and heart growth in salmonids 
Previous studies by our group indicate that a high post-stress cortisol level is associated with 
cardiac remodeling and altered gene expression in salmonid fishes (Johansen et al., 2011). In 
two strains of rainbow trout that have been selected for divergent post-stress cortisol levels 
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(high responsive: HR, and low responsive; LR) the HR fish had larger hearts than LR fish. 
This increased heart size was found mainly to be due to hypertrophy of the compact 
myocardium. Several known markers of heart pathology (VMHC, SMLC2 and RCAN1) from 
human cardiology were up-regulated in HR hearts and cortisol receptors were highly 
expressed indicating that these animals are sensitive to the actions of cortisol. To confirm the 
divergence in heart size outside the HR-LR model, the authors investigated the relationship 
between heart size and cortisol-responsiveness in wild-type European brown trout and found a 
positive correlation also in this salmonid species.  
To investigate the isolated effect of cortisol on the fish heart Johansen et al. 
(unpublished) performed a feeding experiment where unselected rainbow trout were fed 
cortisol-enriched feed for 45, 70, 80 and 90 days. 45 days of cortisol treatment induced a 34% 
increase in relative ventricle weight (Johansen et al. unpublished) and supported the 
hypothesis that it was cortisol that induced the hypertrophy in the previous study. Several 
markers of heart pathology from human cardiology were up-regulated in cortisol treated fish 
including SMLC, MLP and ANP. No further increase in ventricle size was observed with 
treatments longer than 45 days. 
Since fish do not produce aldosterone and cortisol is the main ligand for both the MR 
and GR it is possible that cortisol mimics the role aldosterone has in cardiac pathology in 
humans.  It would be interesting if the mechanism whereby (inappropriate) activation of MR 
induces cardiac pathology is evolutionarily conserved from fish to mammals.  
As a first step towards unraveling the mechanisms by which cortisol induces heart 
growth in salmonids, we wanted to block the different receptors for cortisol by using cortisol-
receptor antagonists and investigate through which receptor(s) cortisol is acting when 
inducing heart growth. The GR antagonist mifepristone has known anti-glucocorticoid effects 
in fish and was evaluated by Mommsen et al. (1999) to be an excellent tool for blocking the 
fish GR. Since a MR was only recently discovered in fish, few studies have aimed at blocking 
the MR. The MR antagonist spironolactone has known anti-mineralocorticoid effects in 
mammals and amphibians and was recently shown to block the MR also in trout (Sloman et 
al., 2001; Schjolden et al., 2009).  
In the current study, we aimed at investigating receptor-specific effects of cortisol both 
at the phenotypic and molecular level. We assumed that possible effects of the blockers would 
be easier to detect at a time-point when the heart is in a steep growth phase since that is when 
we would expect the highest expression of genes mediating the response to cortisol (cortisol-
responsive genes). Johansen et al. (unpublished) showed that after about 45 days of treatment 
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the hearts did not grow further, thus the time-point at which the heart was growing actively 
had to be earlier than 45 days. We therefore first wanted to determine a time-course for the 
heart growth.   
Accordingly, the overall aim of this study was to determine the time-course of the 
cortisol-induced heart growth and try to investigate receptor-specific effects of cortisol both at 
the phenotypic and molecular level.  
To get a time-course of the heart growth we investigated the relative ventricle weight 
of rainbow trout after 2, 7 and 21 days of cortisol treatment by daily intake of cortisol-
enriched pellets (in the following referred to as the time-course experiment). We aimed at 
determining when the heart growth could first be observed and by comparing the data from 
this study with the data from cortisol treatment for 45 days, determine a time point at which a 
steep growth phase could be ensured. 
In the time-course experiment we found a marked heart growth after 21 days and 
therefore decided to perform the blocking experiment for 21 days. To investigate the receptor-
specific effects of cortisol on the observed cardiac remodeling we thus performed a new 
feeding experiment where rainbow trout were fed feed enriched with (1) cortisol, (2) cortisol 
and the MR antagonist spironolactone, (3) cortisol and the GR antagonist mifepristone, or (4) 
cortisol and both antagonists, for 21 days (in the following referred to as the antagonist 
experiment). The relative ventricle weight and the mRNA abundance of genes (cardiac 
marker genes) linked to cardiac hypertrophy and hyperplasia, vascularization, and fibrosis, 
were investigated. We hypothesized that since the mineralocorticoid receptor is implicated in 
cardiac pathologies in humans, the effect of cortisol might be mediated through the MR. 
  
12 
 
1.5 Aims of study 
I.  Time-course experiment 
Determine the time-course of the heart growth observed in cortisol-fed rainbow trout 
 Determine when the first heart growth could be observed  
 Determine a time point at which a steep growth phase could be ensured 
II. Antagonist experiment 
Investigate through which receptor(s) cortisol mediates heart growth in rainbow tout 
 Investigate receptor –specific effects on heart phenotype 
 Investigate receptor-specific effects on the mRNA abundance of genes 
mediating the response to cortisol  
  
13 
 
2 MATERIALS AND METHODS 
2.1 Experimental animals 
The experimental animals were juvenile rainbow trout. The animals that were used in the 
time-course experiment were obtained from a commercial breeder (Valdres Ørretoppdrett Røn 
Gård, Valdres, Norway) while the animals that were used in the antagonist experiment were 
obtained from the Department of Animal and Aquacultural Sciences (University of Life 
Sciences, Norway). Both studies were conducted at the fish holding facilities of the 
Department of Biosciences at the University of Oslo.  
Prior to each of the experiments approximately 200 individuals were held in a 1250 L 
holding tank (250x100x50cm) for at least 3 weeks. The holding tank was continuously 
supplied with dechlorinated Oslo tap water (1000 l/h) at 5-7°C with a light regime of 12 hours 
light and 12 hours darkness. During this period the fish were fed once daily with commercial 
trout pellets (EFICO, Enviro, 920, Biomar, Brande, Denmark) corresponding to 1% of their 
body weight. A total of 48 fish weighing from 107.0 g to 242.0 g (166.0 g ±4.3 g) were used 
for the time-course experiment. For the antagonist experiment 80 fish weighing from 139.4 g 
to 298.5 g (212.7 g ± 4.2 g) were used. The time-course experiment was conducted in March 
while the antagonist experiment was conducted in June. 
2.2 Experimental set-up and procedure 
2.2.1 Time-course experiment 
The experimental set-up consisted of eight 250 L glass aquaria (100x50x50cm) divided into 
four equally sized compartments by opaque PVC-walls. The sides and the bottom of each 
aquarium were covered on the outside with black plastic film. The aquaria were continuously 
aerated and supplied with dechlorinated Oslo tap water (0.25 l/min, 5-7°C, 12h/12h 
light/darkness). 
At the time of insertion, the fish were taken from the holding tank and mildly 
anesthetized in a bath of 0.25 g/l tricaine methanesulfonate (MS-222, Sigma-Aldrich, St. 
Louis, MO, USA). They were weighed and transferred to isolation in the compartments of the 
aquaria. The fish were allowed to acclimate for 12 days.  
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During acclimation the fish were fed commercial trout pellets once daily between 
10.00 and 14.00 pm by dropping pellets one by one into the aquarium. The fish were fed to 
satiation or equivalent to 0.8% of their body weight. The number of pellets remaining at the 
bottom of each compartment 10 minutes after the feeding was recorded in order to calculate 
how much each fish was eating. The remaining pellets were removed. Unfortunately several 
fish were eating poorly during acclimation. We decided to go ahead with the experiment after 
12 days of acclimation, when all, except three fish, were consuming feed corresponding to 
>0.3% of their body weight daily. The three fish that were not eating during acclimation were 
removed from the experiment. 
The fish were to be fed with a daily ration of either control feed or cortisol (4 µg/g 
bodyweight (BW)) enriched feed for 2, 7 or 21 days. Fish in the same aquarium (but separated 
by the PVC walls) were given the same diet. Accordingly, the aquariums were assigned at 
random to the following diets; control 2 days (cont2d, n=7), cortisol 2 days (cort2d, n=8), 
control 7 days (cont7d, n=7), cortisol 7 days (cort7d, n=8), control 21 days (cont21d, n=8) and 
cortisol 21 days (cort21d, n=7). A comparison of the body weights measured at insertion 
showed no significant difference in body weight between the groups (ANOVA; F(5,42)=0.55, 
p=0.75). During the experiment, feeding was monitored and feed removed in the same 
manner as during acclimation.  
2.2.2 Antagonist experiment 
In the time-course experiment we experienced that 8 individuals in each group was somewhat 
low because we risk losing experimental animals because they are not eating. To increase the 
statistical power we therefore chose to increase the size of the treatment groups in this 
experiment. This was only feasible if several individuals were held together in each aquarium. 
Accordingly, 80 individuals were taken from the holding tank, anesthetized in 0.25 mg/l MS-
222, and 8 individuals were distributed (to obtain approximately the same size distribution in 
each aquarium) to each of ten (2 duplicates per group) 250L glass aquaria (100x50x50cm) 
which were continuously aerated and supplied with dechlorinated Oslo tap water (0.25 l/h, 8-
9°C, 12 h/12h light/darkness). The fish were acclimated for 10 days. Eight days into the 
acclimation, the fish were once again anesthetized in 0.25 mg/l MS-222, weighed, measured 
and tagged with a passive integrated transponder (PIT) tag in order to monitor changes to their 
weight during the experiment. The fish were then transferred back to their proper aquarium. 
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Unfortunately, the feeding pattern of each individual could not be monitored with this 
set-up. To get a measure of how much the fish were eating as a group the pellets left at the 
bottom of the aquarium 10 minutes after each feeding were removed, dried in room 
temperature overnight and weighed. The weight of the dried pellets was used to calculate 
approximately how many pellets had not been eaten and were subtracted from the total 
number of pellets that were fed to the fish. When rainbow trout are held together, a social 
hierarchy is soon established and a dominant individual might prevent some fish from eating. 
To increase the probability that all individuals had the opportunity to eat, the fish were fed at 
three time points daily (10.00, 14.00 and 16.00 pm) with a daily total feed equivalent to 0,8 % 
of the total body weight in the aquarium both during acclimation and during the treatment 
period. Feeding behavior was monitored visually and all fish were actively seeking the food at 
the start of the experiment.  
After acclimation, the fish were assigned to one of five feeding regimes (n=16 in each 
group) for 21 days; control (CONT), cortisol (CORT) (4 µg/g BW), cortisol and the MR 
antagonist spironolactone (CORT+MR) (0.46 µg/g BW), cortisol and the GR antagonist 
mifepristone (CORT+GR) (2.3 µg/g BW), and cortisol in combination with both antagonists 
(CORT+BA). A comparison of the body weights recorded after marking with PIT-tags 
showed that there was no significant difference in weight between the groups (ANOVA; 
F(4,75)=0.11, p=0.98).  
For practical reasons, 5 aquaria were started on the feeding regime after 10 days of 
acclimation and the remaining 5 after 11 days of acclimations and were thus sampled over 
two subsequent days. 
2.3 Preparation of experimental feed 
Each of the experimental diets were prepared by dissolving cortisol (hydrocortisone powder, 
Sigma-Aldrich) alone or together with the antagonists spironolactone (powder, Sigma-
Aldrich) and/or mifepristone (powder, Sigma-Aldrich) in rape seed oil by the use of a 
magnetic stirrer. 15 mg of this oil containing 500 mg cortisol alone or, depending on 
treatment, together with 57.5 mg spironolactone and/or 290 mg mifepristone, was then 
applied to 1 kg prefabricated pellets inside a vacuum coater (doses were modified from 
Schjolden et al. (2009)). This container had two valves; one was for letting in air and the other 
was coupled to a vacuum pump. In order to draw the cortisol into the pellets, a negative 
pressure of 0.9 Bar was applied. At 0.9 Bar we closed the valve connected to the vacuum 
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pump and mixed the feed by shaking the container by hand ten times. Thereafter, the valve 
was opened to let in some air and closed again before the container was shaken ten more 
times. Once more, the valve was opened, some air let in, valve closed and the container 
shaken ten times. This whole procedure (applying vacuum, letting in air and shaking) was 
repeated twice for each feed type. Control feed was prepared in the same way but with the 
application of pure rape seed oil. 
2.4 Sampling 
The sampling protocol was essentially the same in the two experiments and any differences 
are pointed out. Sampling was conducted between 09.00 and 13.00 pm the day after the last 
feeding. The fish were taken from their aquarium in random order and anesthetized in a bath 
of 1 mg MS-222/l water. In the antagonist experiment the PIT-tag was removed and the code 
recorded. The fish were weighed and a blood sample was collected from the caudal vein 
before the fish were sacrificed by decapitation. The blood samples were kept on ice for no 
more than 45 min until they were centrifuged for 5 min at 4°C, 8000 g. Plasma was frozen 
and stored at -20°C for later analysis of cortisol levels. The hearts were surgically excised and 
the bulbus and atrium removed. The ventricles were weighed on a precision weight and the 
cardiosomatic index (CSI=ventricle weight/body weight), was calculated. The ventricles were 
cut into two approximately equal halves and placed in 1.5 ml RNAlater solution (Ambion, 
Austin, TX, USA). Ventricles on RNAlater were left at room temperature for 24 hours 
according to the manufacturer’s recommendations and subsequently stored at -20°C. In the 
time-course experiment, all 48 ventricles were placed on RNAlater. In the antagonist study 12 
ventricles from each treatment group were placed on RNAlater. Physiological data on the 
study animals in the time-course experiment and antagonist experiment are presented in  table 
4 and 5, respectively in Appendix B.  
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2.5  RNA extraction and quantitative real time-PCR 
analysis 
Total RNA was extracted from the ventricles using Trizol reagent (Invitrogen, Carlsbad, CA, 
USA) according to the manufacturer’s protocol. Extractions were performed in random order. 
The tissue samples were homogenized in Trizol reagent at a ratio of 15 µl Trizol/mg tissue. 
The RNA was treated with DNase using the TURBO DNA-free Kit (Invitrogen). The purified 
RNA was quantified using the NanoDrop ND-2000 UV-Vis Spectrophotometer (Thermo 
Fisher Scientific Inc., Wilmington, DE, USA). RNA quality was confirmed using the 2100 
Bioanalyzer (Agilent Technologies Inc., Santa Clara, CA). The RIN score ranges from 1 to 
10, where level 10 RNA is completely intact. The RIN for the tissue samples ranged from 
8.40 to 10 with an average of 9.3 ± 0.03 (mean ± s.e.m.), confirming excellent RNA quality. 2 
µg total RNA was reverse transcribed into cDNA using oligo(dT)18-20 primers (Invitrogen) 
and the SuperScript III Reverse Transcriptase Kit (Invitrogen).  
Quantitative real-time PCR (qRT-PCR) reactions were performed with the 
LightCycler480 Real-Time PCR System (Roche Diagnostics), using the LightCycler 480 
SYBR Green 1 Master mix (Roche Diagnostics) with 3 µl 1:25x diluted cDNA, 1 µM of each 
primer, for a total reaction volume of 10 µl. All reactions were run in duplicates on different 
plates. The crossing point (Cp) values were calculated by the LightCycler480 software with 
the second derivative maximum method which identifies the Cp of a sample as the point 
where the sample’s fluorescence curve turns sharply upward (LightCycler 480 Instrument, 
Operator’s Manual). This point corresponds to the maximum of the second derivative of the 
amplification curve. The efficiency of each reaction was calculated with the LinReg software 
(version 2012.1). The average efficiency of all reactions for each primer pair was used for 
further calculations. Relative mRNA abundance was calculated from the following formula: 
(ConE
Cp
/GOIE
Cp
), where E is the mean efficiency for the primer pair, Cp is the mean Cp value 
for the two duplicate qPCR reactions, Con is the control gene and GOI is the gene of interest.  
The cardiac marker genes that were used in this study are listed in table 1 together 
with the primers designed to target them and their GenBank accession numbers. Gene specific 
primers had been predesigned by Johansen et al. (2011). Johansen et al. (unpublished) 
evaluated β-actin to be a suitable control gene in cortisol-treatment experiments. For the 
purpose of comparing our results, β-actin was used also in this study. See Appendix A for a 
detailed description of the methods used for RNA extraction and qRT-PCR. 
18 
 
Table 1 Specific marker genes with primers used for qRT-PCR 
Gene Primer pairs: GenBank accession numbers: Function/Marker of: 
β-actin F:AGCCCTCCTTCCTCGGTAT 
R:AGAGGTGATCTCCTTGTGCATC 
NM001124235.1 Housekeeping gene 
PCNA F:AGCAATGTGGACAAGGAGGA 
R:GGGCTATCTTGTACTCCACCA 
EZ763721.1 Cardiomyocyte hyperplasia 
VMHC F:TGCTGATGCAATCAAAGGAA 
R:GGAACTTGCCCAGATGGTT 
AY009126.1 Cardiomyocyte hypertrophy 
SMLC2 F:TCTCAGGCGGACAAGTTCA 
R:CGTAGCACAGGTTCTTGTAGTCC 
NM001124678.1 Cardiomyocyte hypertrophy 
MLP F:AGTTCGGGGACTCGGATAAG 
R:CGCCATCTTTCTCTGTCTGG 
NM001124725.1 Cardiomyocyte hypertrophy 
α-actin F:ACCGGAGTCCAGCACAATAC 
R:ACTGGGACGACATGGAGAAG 
AF503211.1 Cardiomyocyte hypertrophy 
RCAN1 F:AGTTTCCGGCGTGTGAGA 
R:GGGGACTGCCTATGAGGAC 
BC076439.1 (D. Rerio)* NFAT-activity/pathological 
cardiomyocyte hypertrophy 
MR F:CAGCGTTTGAGGAGATGAGA 
R:CCACCTTCAGAGCCTGAGAC 
AY495581.1 Cortisol sensitivity 
GR1 F:AGGTTGTCTCAGCCGTCAAA 
R:GCAGCTTCATCCTCTCATCAT 
NM001124730.1 Cortisol sensitivity 
GR2 F:ACTCCATGCACGAGATGGTT 
R:CGGTAGCACCACACAGTCAT 
NM001124482.1 Cortisol sensitivity 
VEGF F:AGTGTGTCCCCACGGAAA 
R:TGCTTTAACTTCTGGCTTTGG 
AJ717301.1 Angiogenesis 
COL1a2 F:GGTTCGGCGAGACCATTA 
R:GTTGTGTGGCCATGCTCTG 
NM001124207.1 Fibrosis 
COL1a1 F:CGCTTCACATACAGCGTCAC 
R:AATGCCAAATTCCTGATTGG 
NM001124177.1 Fibrosis 
ANP F:CCACAGAGGCTCTCAGACG 
R:ATGCGGTCCATCCTAGCTC 
NM001124211.1 Heart failure 
BNP F:TGGCCTTGTTCTCCTGTTCT 
R:GGAGACTCGCTCAACCTCAC 
NM001124226.1 Heart failure 
VNP F:TATGCCAGTCGGAATGTTCA 
R:CTTTCAGGGGCAATTCTGTT 
NM001124212.1 Teleost specific natriuretic peptide 
Modified from Johansen et al. (2011). F: Forward primer 5’→3’; R:Reverse primer 5’→3’. For full gene names, 
see List of abbreviations. *The rainbow trout RCAN1 sequence was found by BLAST with Danio rerio RCAN1. 
2.6 Radioimmunoassay quantification of plasma cortisol  
To verify that cortisol-treated fish had elevated cortisol levels, plasma cortisol was measured 
in plasma of all experimental fish from the time-course experiment and in a selection of 
individuals from the antagonist study (8 randomly chosen individuals from each group). 
Plasma cortisol was analyzed using a radioimmunoassay based on the assay by Pottinger and 
Carrick (2001). For a description of the radioimmunoassay procedure see Appendix A. 
The lower detection limit of the assay was 0.19 ng/ml. For individuals where the 
plasma cortisol levels were below this limit, the level was set to 0.2 ng/ml. The upper limit 
was 655 ng/ml. For individuals that displayed higher plasma cortisol levels than this, the level 
was set to 650 ng/ml. 
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2.7 Statistical analysis 
Values are presented as mean ± s.e.m. All statistical analyses were performed using GraphPad 
Prism6 (GraphPad Software, San Diego, CA, USA). Data on body weight, growth rate in the 
time-course experiment, feed intake, CSI and mRNA levels (with the exception of BNP, 
PCNA and SMLC2) fulfilled the requirements for parametric analysis and were analyzed by 
parametric ANOVA, followed by Tukey HSD post-hoc tests where relevant. Data on plasma 
cortisol levels, growth rate in the antagonist-experiment and mRNA levels of BNP, PCNA 
and SMLC2 did not show variance homogeneity (as shown by Brown-Forsythe test) and were 
transformed (log or inversely as appropriate) prior to analysis. Differences were considered 
significant for p<0.05. 
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3 RESULTS 
3.1 Plasma cortisol levels 
3.1.1 Time-course experiment 
To confirm that cortisol treated fish had increased plasma cortisol levels compared to normal 
control values, plasma cortisol levels were measured in all individuals from all groups. 
Plasma cortisol levels were compared between groups by two-way ANOVA with time and 
treatment as response variables, followed by Tukey HSD post hoc test. Mean plasma cortisol 
concentrations (ng/ml) are presented in figure 2 while the ANOVA was performed on log-
transformed data, a transformation which yielded variance homogeneity between groups 
(Brown-Forsythe test, p=0.49).  
There was a significant effect of treatment (ANOVA; F(1,42)=165.9, p<0.001) with 
cortisol treatment for 2, 7 and 21 days giving significantly higher plasma cortisol levels than 
in their controls (p<0.001 in all cases). There was also a significant effect of time (ANOVA; 
F(2,42)=5.33, p<0.01), and an interaction between time and treatment (ANOVA; F(2,42)=3.50, 
p<0.01), with plasma cortisol levels being significantly higher after two days of cortisol 
treatment than after 7 and 21 days of treatment (p<0.05 in both cases).  
 
Figure 2 Effect of 2, 7 and 21 days of cortisol treatment on plasma cortisol levels  
Plasma cortisol levels (ng/ml) for all groups (Con2d (n=7), Cort2d (n=8), Con7d (n=7), Cort7d (n=8), Con21d 
(n=8), and cort21d (n=7)), presented as mean ± s.e.m. Statistical differences between groups were tested by two-
way ANOVA analysis on log transformed data followed by Tukey HSD post-hoc test. Only significant 
differences between the cortisol groups and their respective control, and between the cortisol groups are shown 
(*= p<0.05 and ****= p<0.001). 
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3.1.2 Antagonist experiment 
Cortisol levels were measured in the plasma of eight individuals from each group to confirm 
that cortisol treatment gave increased plasma cortisol levels compared to normal control 
values. Plasma cortisol levels were compared between groups by one-way ANOVA and 
Tukey HSD post hoc test. Mean plasma cortisol concentrations (ng/ml) are presented in figure 
3 while the ANOVA was performed on log-transformed data, a transformation which yielded 
variance homogeneity between groups (Brown-Forsythe test, p=0.20).   
All treatment groups showed significantly increased plasma cortisol levels compared 
to the control group (p<0.001 for all treatment groups). Interestingly, plasma cortisol levels 
were significantly higher in the CORT+BA group compared to the CORT group (p<0.05) and 
there was a clear trend towards higher plasma cortisol levels in the CORT+GR group 
compared to the CORT group (p=0.11), but not in the CORT+MR group (p=0.91).  
  
 
Figure 3 Effect of treatment with cortisol, alone or in combination with receptor antagonists on plasma 
cortisol levels  
Plasma cortisol levels for 8 individuals from each group (CONTROL, CORTISOL, CORT+BA, CORT+MR and 
CORT+GR), presented as mean ± s.e.m. Statistical differences were tested by one-way ANOVA analysis on log 
transformed data followed by Tukey HSD post hoc test and are indicated by different letters (a/b/c/d).    
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3.2 Body weight, growth rate and feed intake 
3.2.1 Time-course experiment 
Growth rate and body weight was compared between groups by one-way ANOVA and Tukey 
HSD post-hoc test. Growth rate is presented as mean ± s.e.m in figure 4.A. There was a 
significant effect of cortisol treatment on growth rates, in that specific growth rate (percentage 
body weight change per day) was significantly reduced by 21, but not 2 or 7 days of cortisol 
treatment (Cort21d; p<0.01, Cort2d; p=0.98 and Cort7d; p=0.93). This resulted in cortisol 
treated fish being significantly smaller than untreated controls at day 21 (p<0.05). This effect 
on body size was however not evident after 2 or 7 days of cortisol treatment (p=0.99 and 
p=0.80, respectively). The observed reduction in body weight after 21 days of cortisol 
treatment could be, at least partly, due to the negative effect of cortisol on feed intake.  
During the experiment we observed that cortisol treated fish ate less than control fish. 
To investigate if there was a significant difference in feed intake between control fish and 
cortisol treated fish, the mean feed intake for each individual (in percent of its body weight) in 
all groups was calculated and compared by one-way ANOVA and Tukey HSD post hoc tests 
(Figure 4.B). Fish treated with cortisol for 7 and 21 days showed a significantly lower feed 
intake per day compared to their controls (p<0.01 and p<0.001, respectively). This effect was 
not apparent after 2 days of cortisol treatment (p=0.85). 
 
Figure 4 Growth rate was significantly reduced by 21 days of cortisol treatment  
Specific growth rate (percentage body weight change per day) (A) and mean feed intake per day in percentage of 
body weight (B), for all groups (Con2d (n=7), Cort2d (n=8), Con7d (n=7), Cort7d (n=8), Con21d (n=8), and 
Cort21d (n=7)), presented as mean ± s.e.m. The study animals were fed pellets corresponding to 0.8% of their 
body weight daily. Statistical differences were tested by one-way ANOVA analysis and Tukey HSD post hoc 
test. Only significant differences between the treatment groups and their respective control is shown (**= p<0.01 
and ****= p<0.001).   
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3.2.2 Antagonist experiment 
Growth rate and body weight was compared between groups by one-way ANOVA and Tukey 
HSD post-hoc test. Growth rate is presented as mean ± s.e.m in figure 5.A. The ANOVA was 
performed on log-transformed data, a transformation which yielded variance homogeneity 
between groups (Brown-Forsythe test, p=0.25).   
Also in this experiment, cortisol treatment had a significant negative effect on specific 
growth rate of the study animals. All treatment groups had a significantly lower growth rate 
than the controls (p<0.001 in all cases). Interestingly, the CORT+BA and the CORT+GR 
groups showed significantly higher growth rates than the CORT group (p<0.001 in both 
cases) and CORT+MR group (CORT+BA: p<0.01 and CORT+GR: p<0.001). In accordance 
with these results CORT and CORT+MR treated fish were significantly smaller than the 
controls (p<0.01 and p=0.001, respectively), while CORT+GR treated fish were not 
significantly smaller than the controls (p=0.26). The CORT+BA group showed a 
nonsignificant reduction in body weight compared to the controls (p=0.06).  
To investigate the feed intake of cortisol and receptor antagonist-treated fish, we 
calculated the average number of pellets consumed by each group per day in percentage of the 
total pellets fed and compared the feed intake between groups by one-way ANOVA and 
Tukey HSD post hoc tests. Feed intake is presented as mean ± s.e.m in figure 5.B. Similarly 
to what was seen in the time-course experiment, cortisol treatment resulted in a lower feed 
intake per day also in this experiment (p<0.001). The CORT+BA group showed a similar 
reduction to that of the CORT group. Interestingly, the CORT+MR treated group showed a 
tendency toward lower feed intake than the CORT group (p=0.09). In the CORT+GR group, 
on the other hand, the effect of cortisol was almost entirely abolished.  
 
Figure 5 Feed intake was partially blocked by the GR antagonist and is reflected in a higher growth rate 
in GR treated fish compared to fish that got only cortisol  
A: Specific growth rate (percentage body weight change per day), B: average pellets eaten per day (in percent of 
total pellets fed) for all groups (CONTROl, CORTISOL, CORT+BA, CORT+MR and CORT+GR), presented as 
mean ± s.e.m, n=16 (except CORT+MR group, n=15). Statistical differences between groups were tested by one-
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way ANOVA (growth rate data was first log transformed) and Tukey HSD post Hoc test and are indicated by 
different letters (a/b/c).  
3.3 Relative ventricle weight 
3.3.1 Time-course experiment 
To identify the time-course of the heart growth, CSIs were calculated from the weight of 
freshly excised ventricles of fish treated with cortisol for 2, 7 and 21 days and their controls. 
CSIs were compared between groups by two-way ANOVA with respect to time and treatment 
followed by Tukey HSD post hoc test. Mean CSIs are shown in percentage relative to their 
respective control in table 2 and as mean ± s.e.m in figure 6.  
There was both an effect of time and of cortisol treatment on CSI, but no interaction 
effect (effect of time: F(2,39)=7.43, p<0.01, effect of treatment F(2,39)=8.54 , p<0.01, interaction 
between factors= F(2,39)= 0.35, p=0.70). There was no significant difference in CSI between 
the three control groups but there was a clear tendency towards an increased CSI in the 21 day 
control group. The CSI of this control group was 21.8% higher than the 2 days control group 
(p=0.12). Possible causes for this higher CSI are discussed below.  
Mean CSI after 21 days of cortisol treatment was significantly higher than for the 2 
days and the 7 days controls (p<0.01 in both cases), but not significantly higher than the 21 
days controls (p=0.73). 2 and 7 days of cortisol treatment resulted in non-significant increases 
in CSI compared to their controls (p=0.25 and p=0.89, respectively). Notably, the mean CSI 
of fish treated with cortisol for 2 days was 18.7% higher than its control. There was no 
significant effect of gender on CSI in any of the groups (ANOVA; F(1,34)=0.08, p=0.78). 
 
Table 2 Mean CSI for each group in percent of their control group 
 Control Cortisol 
2 days 100.00±5.11 118.7±6.10 
7 days 100.00±3.97 108.3±5.78 
21 days 100.00±4.24 112.20±6.52 
 
26 
 
 
Figure 6 Effect of time and cortisol treatment on cardiosomatic index (CSI)  
Cardiosomatic index (CSI), the ratio of ventricle weight to body weight (g/g) x10
3
, for all groups (con2d (n=7), 
con7d (n=7), con21d (n=8), cort2d (n=8), cort7d (n=8) and cort21d (n=7)), shown as one graphical point per 
group (mean ± s.e.m). Statistical differences were tested by two-way ANOVA analysis followed by Tukey HSD 
post hoc tests (**= p<0.01). See table 4 in Appendix B for detailed CSI values. 
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3.3.2 Antagonist experiment 
Our previous data (Johansen et al. unpublished) and the time-course experiment show that 
cortisol induces heart growth. To investigate which receptor is involved in mediating this 
heart growth, CSIs were calculated from the weight of freshly excised ventricles of fish 
treated with cortisol only, cortisol in combination with receptor antagonists and from controls. 
CSIs were compared between groups by One-way ANOVA followed by Tukey HSD post hoc 
tests and are presented as mean ± s.e.m in figure 7. Mean CSIs are shown in percentage 
relative to their respective control in table 3.   
The CSIs of the cortisol treated fish were significantly higher (20.4%) than that of the 
control fish (p<0.001). The CSIs of the CORT+BA and CORT+GR groups were also 
significantly higher than that of the control group (p<0.001 and p<0.01, respectively) and 
showed similar increases to that of the CORT group. The CSI of the CORT+MR group was 
not significantly higher than the control group although there was a non-significant increase 
of 13.3% (p=0.06). The CSI of the CORT+MR group did however not differ significantly 
from the CORT group either (p=0.60). There was no significant effect of gender on CSI on 
any of the groups (ANOVA; F(1,69)<0.001, p=0.98).  
Table 3 Mean CSI for each group in percent of the control group  
Control Cortisol Cort+BA Cort+MR Cort+GR 
100.0 ± 3.32 120.4 ± 3.41 121.2 ± 3.77 113.3 ± 3.08 117.4 ± 3.53 
 
  
Figure 7 The antagonists did not significantly block the increase in ventricle weight seen in cortisol treated 
fish Cardiosomatic index (CSI), the ratio of ventricle weight (g) to body weight (g) x 10
3
, for all groups 
(Control, Cortisol, Cort+BA, Cort+MR and Cort+GR), n=16 for each group (except Cort+MR group, n=15), 
shown as one graphical point per fish and as mean ± s.e.m. Statistical differences were tested by One-way 
ANOVA followed by Tukey HSD post hoc tests and are indicated by different letters (a/b). See table 5 in 
Appendix B for detailed CSI values. 
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Since cortisol treatment resulted in reduced growth rate and lower body weight, the 
observed difference in CSI between controls and cortisol treated fish could be partly due to 
the higher body weight of the controls. The relationship between body weight and ventricle 
weight and between body weight and CSI was therefore investigated in control fish and 
cortisol-treated fish from the antagonist experiment (Figure 8). The statistical analysis was 
performed using linear regression analysis (least squares method) and Pearson’s product 
moment correlation coefficient as a measure of the resulting linear relationship (r
2
 and p-
values).   
There was a positive correlation between body weight at time of sampling and 
ventricle weight in the control group (Pearson; r
2
=0.50, p<0.01) and the cortisol treated group 
(Pearson; r
2
=0.78, p<0.001), showing that larger fish have larger ventricles. Body weight thus 
accounts for about 50% of the variability in ventricle weight.  
There was no significant correlation between CSI and body weight at the time of 
sampling in the control group (Pearson; r
2
=0.04, p=0.45) or in the cortisol group (Pearson; 
r
2
=0.03, p=0.53), indicating that heart size is matched with body size within the range of body 
weights investigated. The observed differences in CSI are therefore not caused by the higher 
body weight of control fish. In fact, after 45 days of cortisol treatment Johansen et al. 
(unpublished) observed that absolute ventricle weights were significantly higher in cortisol-
treated fish compared to control fish despite of their absolute body weights being significantly 
lower than in the control group.   
Figure 8 The relationship between ventricle weight and body weight and between CSI and body weight 
Correlation between bodyweight (g) and ventricle weight (g) in the control group (r
2
=0.50, p<0.01) and the 
cortisol group (r
2
=0.78, p<0.001) (A) and correlation between body weight (g) and cardiosomatic index (CSI), 
the ratio of ventricle weight (g) to body weight(g) x 103, in the control group (r
2
=0.04, p=0.45) and the cortisol 
group (r
2
=0.03, p=0.53) (B). Each data point represents one individual. The statistical analysis was performed 
using linear regression analysis (least squares method) and Pearson’s product moment correlation coefficient as a 
measure of the resulting linear relationship (r
2
 and p-values).  
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3.4 mRNA levels of cardiac marker genes and cortisol 
receptors 
To investigate receptor-specific effects of cortisol on the observed heart growth, the mRNA 
levels of specific cardiac marker genes and of the cortisol receptors were measured by qRT-
PCR in the ventricles of all treatment groups. The mRNA levels for each gene were compared 
between groups by one-way ANOVA followed by Tukey HSD post hoc tests. All data on 
mRNA levels fulfilled the requirements for parametric analysis except data for PCNA, BNP 
and SMLC2. Data for PCNA and BNP were inversely transformed and data for SMLC2 log 
transformed prior to analysis, transformations which yielded variance homogeneity between 
groups (Brown-Forsythe test; PCNA: p=0.18, BNP: p=0.08, SMLC2: p=0.25). For detailed 
ANOVA statistics see table 6 in Appendix B.  
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mRNA levels of markers of cardiomyocyte hypertrophy were increased after 21 days of 
cortisol treatment 
The mRNA levels of markers for cardiomyocyte hypertrophy, VMHC, SMLC2, MLP and α-
actin, were measured in all treatment groups (Figure 9).  
VMHC and SMLC2 mRNA levels were significantly increased in all treatment groups 
compared to the controls. Cortisol treatment resulted in a 1.49-fold increase in VMHC levels 
compared to the controls (p<0.001). The CORT+BA, CORT+MR and CORT+GR groups 
showed similar increases in VMHC levels to that of the CORT group. There was a 4.13-fold 
increase in SMLC2 levels in the CORT group compared to the controls (p<0.001). The 
CORT+BA, CORT+MR and CORT+GR groups showed similar increases in SMLC2 levels 
to that of the CORT group. The mRNA levels of MLP and α-actin were not significantly 
affected by any of the treatments. 
 
Figure 9 mRNA levels of the hypertrophy markers VMHC and SMLC2, but not MLP and α-actin, were 
increased in the ventricle of fish treated with cortisol for 21 days 
mRNA levels of ventricular myosin heavy chain (VMHC) (A), slow myosin light chain 2 (SMLC2) (B), muscle 
LIM protein (MLP) (C) and α-actin (D) relative to the standard gene β-actin in the ventricles of all groups 
(CONTROL, CORTISOL, CORT+BA, CORT+MR and CORT+GR), presented as mean ± s.e.m. relative to 
control levels, n=12. Statistical differences were tested by one-way ANOVA analysis followed by Tukey HSD 
post hoc tests and are indicated by different letters (a/b). SMLC2 was log transformed prior to analysis. See table 
6 in Appendix B for detailed ANOVA statistics. 
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The mRNA levels of the cell proliferation marker PCNA were decreased in the ventricle 
after 21 days of cortisol treatment 
To investigate receptor specific effects of cortisol on cell proliferation in the fish ventricles, 
the cell proliferation marker PCNA was measured in all treatment groups (Figure 10).  
PCNA mRNA levels were significantly reduced in all treatment groups compared to 
the controls. Cortisol treatment reduced PCNA levels 3.03-fold relative to the control 
(p<0.001). Interestingly, the CORT+BA group showed significantly higher levels of PCNA 
than the CORT group and the CORT+MR group (p<0.001 and p<0.001, respectively), but did 
not differ significantly from the CORT+GR group (p=0.13). Furthermore, the CORT+GR 
group showed a clear tendency towards higher mRNA levels compared to the CORT group 
(p=0.06). 
 
Figure 10 PCNA mRNA levels were decreased in the ventricles after 21 days of cortisol treatment  
mRNA levels of proliferating cell nuclear antigen (PCNA) relative to the standard gene β-actin in the ventricles 
of all groups (CONTROL, CORTISOL, CORT+BA, CORT+MR and CORT+GR), presented as mean ± s.e.m. 
relative to control levels, n=12. Statistical differences were tested by one-way ANOVA analysis on inversely 
transformed data followed by Tukey HSD post hoc tests and are indicated by different letters (a/b). See table 6 in 
Appendix B for detailed ANOVA statistics. 
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The mRNA levels of RCAN1, an indicator of pro-hypertrophic NFAT signaling, were 
not significantly increased by cortisol treatment for 21 days  
The calcineurin-NFAT pathway is one of the major pathways involved in pathological 
hypertrophy in mammals. RCAN1 is a direct gene target for the NFAT transcription factor 
and an increased mRNA level of RCAN1 could therefore indicate NFAT-activity. RCAN1 
mRNA levels were measured in all treatment groups (Figure 11).  
There was no significant effect of any of the treatments on RCAN1 levels, but there 
was a non-significant tendency of higher RCAN1 levels in the CORT+BA group (1.34-fold, 
p=0.09) and the CORT+GR group (1.31-fold, p=0.14), compared to the control group.  
 
Figure 11 RCAN1 mRNA levels were not significantly increased in the ventricles after 21 days of cortisol 
treatment 
mRNA levels of regulator of calcineurin 1 (RCAN1) relative to the standard gene β-actin in the ventricles of all 
groups (CONTROL, CORTISOL, CORT+BA, CORT+MR and CORT+GR), presented as mean ± s.e.m. relative 
to control levels, n=12. Statistical differences were tested by one-way ANOVA analysis followed by Tukey HSD 
post hoc tests and are indicated by different letters (a/b). See table 6 in Appendix B for detailed ANOVA 
statistics.  
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mRNA levels of the angiogenesis marker VEGF were not increased after 21 days of 
cortisol treatment  
Cardiac hypertrophy is often accompanied by increased vascularization. Therefore the mRNA 
levels of the angiogenesis marker VEGF were measured (Figure 12).  
There was no significant effect of any of the treatments on VEGF mRNA levels. 
 
Figure 12 VEGF mRNA levels were not significantly increased after 21 days of cortisol treatment  
mRNA levels of vascular endothelial growth factor (VEGF) relative to the standard gene β-actin in the ventricles 
of all groups (CONTROL, CORTISOL, CORT+BA, CORT+MR and CORT+GR), presented as mean ± s.e.m. 
relative to control levels, n=12. Statistical differences were tested by one-way ANOVA analysis followed by 
Tukey HSD post hoc tests and are indicated by different letters (a/b). See table 6 in Appendix B for detailed 
ANOVA statistics.  
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Collagen mRNA levels were reduced in the ventricle after 21 days of cortisol treatment 
and this reduction was partially blocked by the GR antagonist 
An increase in collagen mRNA levels could indicate fibrosis which is a hallmark of 
pathological cardiac remodeling in mammals. Therefore the mRNA abundances of two 
markers of collagen synthesis, COL1α1 and COL1α2, were measured (Figure 13).  
Cortisol treatment alone significantly reduced the mRNA levels of COL1α1 by 1.75-
fold and COL1α2 by 1.89-fold compared to the controls (p<0.001 in both cases). 
Interestingly, this effect was partially blocked by the GR antagonist; the mRNA levels of both 
COL1α1 and COL1α2 were significantly higher in the CORT+GR group compared to the 
CORT group (COL1α1: p=0.001 and COL1α2: p<0.01) and the CORT+MR group (COL1α1: 
p<0.001 and COL1α2: p=0.001), but did not differ significantly from the control group 
(p=0.26 and p=0.27, respectively). Similarly, the mRNA levels of both COL1α1 and COL1α2 
were significantly higher in the CORT+BA group compared to the CORT group (COL1α1: 
p=0.03 and COL1α2: p=0.04) and the CORT+MR group (COL1α1: p<0.01 and COL1α2: 
p<0.01), and did not differ significantly from the control group although there was a trend 
towards lower mRNA levels compared to the controls (COL1α1: p=0.07 and COL1α2: 
p=0.10). The CORT+MR group, on the other hand, showed similar decreases in mRNA levels 
to that of the CORT group. 
 
Figure 13 Collagen mRNA levels were reduced after 21 days of cortisol treatment and this reduction was 
partially blocked by the GR antagonist  
mRNA levels of the collagen α 1(1) (COL1α1) (A) and collagen α 2(1) (COL1α2) (B) relative to the standard 
gene β-actin in the ventricles of all groups (CONTROL, CORTISOL, CORT+BA, CORT+MR and CORT+GR), 
presented as mean ± s.e.m. relative to control levels, n=12. Statistical differences were tested by one-way 
ANOVA analysis followed by Tukey HSD post hoc tests and are indicated by different letters (a/b). See table 6 
in Appendix B for detailed ANOVA statistics. 
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ANP, BNP and VNP mRNA levels were not significantly increased in the ventricles after 
21 days of cortisol treatment 
The natriuretic peptides ANP and BNP are sensitive markers of heart failure in mammals. 
mRNA levels of these markers and the fish specific VNP, were measured in the ventricles of 
all treatment groups (Figure 14).  
Neither ANP, BNP nor VNP mRNA levels were significantly affected by any of the 
treatments. 
 
Figure 14 Natriuretic peptide mRNA levels were not significantly changed by cortisol treatment for 21 
days  
mRNA levels of the atrial natriuretic peptide (ANP) (A), brain natriuretic peptide (BNP) (B) and ventricular 
natriuretic peptide (VNP) (C) relative to the standard gene β-actin in the ventricles of all groups (CONTROL, 
CORTISOL, CORT+BA, CORT+MR and CORT+GR), presented as mean ± s.e.m. relative to control levels, 
n=12. Statistical differences were tested by one-way ANOVA analysis followed by Tukey HSD post hoc tests 
and are indicated by different letters (a/b). BNP was inversely transformed prior to analysis. See table 6 in 
Appendix B for detailed ANOVA statistics. 
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Cortisol receptor mRNA levels were not significantly changed by 21 days of cortisol 
treatment  
To investigate whether treatment with cortisol and antagonists results in changes to the 
expression of cortisol receptors in the ventricles, the mRNA levels of the three cortisol 
receptors were measured (Figure 15).  
None of the treatments had a significant effect on MR, GR1 or GR2 mRNA levels. 
 
Figure 15 mRNA levels of the cortisol receptors were not significantly changed in any of the treatment 
groups 
mRNA levels of the mineralocorticoid receptor (MR) (A), glucocorticoid receptor 1 (GR1) (B) and 
glucocorticoid receptor 2 (GR 2) (C) relative to the standard gene β-actin in the ventricles of all groups 
(CONTROL, CORTISOL, CORT+BA, CORT+MR and CORT+GR), presented as mean ± s.e.m. relative to 
control levels, n=12. Statistical differences were tested by one-way ANOVA analysis followed by Tukey HSD 
post hoc tests and are indicated by different letters (a/b). See table 6 in appendix B for detailed ANOVA 
statistics. 
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4 DISCUSSION 
The main findings of this study were firstly, that 21 days of oral cortisol administration 
induced a 20 % and significant heart growth in rainbow trout. Our results indicate that the 
hearts might be growing already after 2 days of cortisol administration, although this increase 
(19 %) was not statistically significant. Combined with previous results (Johansen et al. 
unpublished) showing that the heart size increase reaches 36% after 45 days of cortisol 
administration, this suggests that the heart is in a steep growth phase around 21 days of 
cortisol treatment. This observation is supported by the analysis of mRNA abundances 
showing high mRNA levels of hypertrophy markers after cortisol treatment. We were not able 
to block the heart growth by administering feed enriched with cortisol receptor antagonists in 
addition to cortisol. This does not necessarily mean that the cortisol receptors are not involved 
in mediating this effect of cortisol, as will be discussed below. Moreover, we found that 
cortisol-treatment decreased the mRNA levels of the markers of collagen synthesis COL1α1 
and COL1α2 and the proliferation marker PCNA and suppressed feed intake and growth. We 
were able to partially block the suppressive effect of cortisol on these targets by use of the GR 
antagonist mifepristone. This indicates that the cardiac GR mediates the effects of cortisol on 
these targets. 
4.1 Relative ventricle weight 
In the time-course experiment we found that relative ventricle weight was significantly higher 
after 21 days of cortisol treatment compared to both the 2 day control and the 7 day control. 
The relative ventricle weight of the control fish after 21 days was unexpectedly high and there 
was no significant difference between this control group and the 21 day cortisol-treated group. 
It seems unlikely that the high ventricle weight in the 21 day control group was a result of 
heart growth during the experimental period. There is considerable natural variation in heart 
size in salmonid fishes (Gamperl and Farrell, 2004) and it cannot be excluded that we, by 
coincidence, obtained fish with naturally large hearts for the 21 day control group. We did not 
observe any significant heart growth with cortisol treatments shorter than 21 days. 
Interestingly, there was an indication of a substantial (19% increase in CSI, p=0.25), 
although not significant, growth after only 2 days of treatment. It is perhaps not entirely 
inconceivable that the fish heart can grow this fast considering the high potential for both 
hypertrophic and hyperplasic cardiac growth in salmonids fishes. In mammals, cardiac 
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hypertrophy can develop very fast. Koide and Rabinowitz (1969) reported significant 
increases in heart weight only 48 hours after banding of the ascending aorta of rats. However, 
the heart growth was not so conspicuous after 7 days of cortisol treatment (8% increase in 
CSI, p=0.89). It would nonetheless be interesting to perform a new 2 day experiment with a 
larger sample size to determine if the heart mass is in fact increased already after 2 days of 
cortisol treatment.    
The heart growth we observed after 21 days of cortisol treatment in the time-course 
experiment was confirmed in the antagonist experiment, where we used a larger number of 
individuals, and showed that cortisol treatment induced an increase in relative ventricle 
weight of 20% compared to controls sampled simultaneously. This strengthens our 
assumption that the unexpected increase in heart size previously seen in 21 day controls was 
coincidental, and is also in line with a previous experiment where cortisol treatment for 45 
days induced a 36% increase in relative ventricle weight (Johansen et al. unpublished). The 
low sample number in the time-course experiment prevents us from drawing conclusions 
about whether significant growth can be observed earlier than 21 days.  
Neither the MR antagonist spironolactone, the GR antagonist mifepristone nor a 
combination of these blocked the effect of cortisol on heart phenotype in this study. We can 
however not rule out that one or both of these receptors are involved in mediating the effect 
on heart phenotype. It is possible that the antagonists were not working optimally and since 
we did not observe any effects of the MR blocker spironolactone it might not have been 
working at all. This will be discussed in detail below.  
4.2 Hypertrophy versus hyperplasia 
The salmonid heart can grow both through hypertrophy and hyperplasia (Farrell et al., 1988; 
Gamperl and Farrell, 2004). We investigated markers of both processes in the hearts of fish 
treated with cortisol alone or with cortisol in combination with receptor antagonists.  
Johansen et al. (2011) suggested that growth of the ventricles of high cortisol 
responsive (HR) fish was mainly due to hypertrophy of the compact myocardium. We found 
that the mRNA levels of VMHC and SMLC2, which are both commonly used hypertrophy 
markers in mammals, were significantly higher in fish fed cortisol for 21 days than in the 
controls, indicating that the heart is undergoing hypertrophic growth. VMHC and SMLC2 
were also highly up-regulated in HR fish compared to low cortisol responding (LR) fish 
(Johansen et al., 2011). After 45 days of cortisol treatment, MLP and SMLC2 were 
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significantly higher expressed than in the controls and VMHC showed a tendency towards up-
regulation (Johansen et al. unpublished). The mRNA levels of SMLC were considerably 
higher after 21 days (4.13-fold) than after 45 days of treatment (1.69-fold). In mammals, these 
are markers of heart disease. We can however not conclude that they have the same function 
in fish. In cold-acclimated rainbow trout, Vornanen et al. (2005) observed a 33% increase in 
heart size and this heart growth was, similarly to our results, associated with increases in 
VMHC and SMLC2 mRNA levels. They interpreted the increase in these gene transcripts to 
be associated with adaptive cardiac hypertrophy.  
These results indicate that hypertrophy is an important part of the hearts growth 
response to cortisol. mRNA levels of VMHC and SMLC2 increases after 21 days of cortisol 
treatment and later in the time-course (after 45 days) the levels of MLP also increases. α-actin 
was not increased after 21 or 45 days of cortisol treatment and was not increased in cold-
induced cardiac hypertrophy either (Vornanen et al., 2005). This could indicate that it is not 
part of the cardiac hypertrophic response in fish. The hypertrophic effect of cortisol was not 
significantly blocked by either spironolactone or mifepristone or a combination of these. 
The proliferation marker PCNA was, on the other hand, not up-regulated. In contrast, 
we found a reduction in the mRNA levels of PCNA after 21 days of cortisol treatment, which 
could indicate reduced cell proliferation at this stage of the heart growth. It is possible that 
PCNA mRNA levels do not reflect PCNA protein levels, but PCNA mRNA levels have been 
assessed to be a reliable and precise indicator of proliferating cells (Köhler et al., 2005). After 
45 days of cortisol treatment PCNA levels were unchanged (Johansen et al. unpublished), 
indicating that the reduction we observe is temporary. In the ventricles of high cortisol 
responding and low cortisol responding fish, PCNA mRNA levels were not significantly 
different either but there was a tendency towards up-regulation in the high cortisol responding 
fish (Johansen et al., 2011). 
Inhibition of cell proliferation by cortisol has been reported for several tissues. 
Cortisol treatment for 6 days, with a similar dose to what we have used, reduced the density of 
PCNA-positive nuclei by 50% in the telencephalon of the rainbow trout (Sørensen et al., 
2011) and in juvenile Atlantic salmon (Salmo salar) with chronically elevated cortisol levels 
following hydrocortisone implantation, division of skin fibroblasts was impaired (Roubal and 
Bullock, 1988). To our knowledge, we are the first to investigate the effects of cortisol on cell 
proliferation in the fish heart.  
Although the majority of cells are myocytes (68%) (Vornanen et al., 2005), the 
salmonid heart is also comprised of other cell-types. The effect of cortisol is likely to be cell 
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type-specific and dependent on the distribution and concentration of cortisol receptors in the 
cells. Since we measured the abundance of mRNA transcripts in the ventricle as a whole and 
have not distinguished between cell types, it could be that the observed reduction in PCNA 
mRNA levels reflects a strong reduction in PCNA mRNA of one cell type. In any case, our 
results do not indicate that the heart grows substantially by proliferation of cardiomyocytes. 
Interestingly, we observed a higher mRNA abundance of PCNA in fish treated with 
both antagonists in combination with cortisol compared to fish treated with cortisol only and 
there was a clear tendency towards higher mRNA levels of PCNA in the group administered 
the GR antagonist in combination with cortisol compared to fish treated with cortisol only 
(p=0.06). Administration of MR antagonist in combination with cortisol did however not 
block this effect. Hu et al. (2012) demonstrated that treatment with the GR antagonist 
mifepristone fully reversed a reduction in PCNA-positive nuclei by cortisol in the rat dentate 
gyrus. Furthermore, cortisol inhibits the proliferation of a rainbow trout fibroblast cell line 
and mifepristone also blocks this effect (Lee and Bols, 1989). This indicates that the 
suppressive effect of cortisol on PCNA mRNA levels is mediated through the GR. An 
explanation for why administration of the GR antagonist alone was not as efficient as 
blocking both receptors could be that both MR and GR are involved in mediating the effect of 
cortisol on cell proliferation in the fish heart and that when only one receptor type is blocked, 
the other compensates. The effect of cortisol was in any case, only partially blocked by the 
antagonists, which could indicate that they were not working optimally. 
4.3 NFAT-signaling 
The calcineurin-NFAT pathway is one of the major pathways involved in pathological 
hypertrophy in mammals. Johansen et al. (2011) showed for the first time that NFAT 
activation occurs in fish. They demonstrated 3-fold higher RCAN1 mRNA levels in HR 
hearts compared to LR hearts. This indicated that the growth of the HR hearts was of 
pathological character. They did however point out that NFAT signaling may serve a more 
physiological role in fish since the fish heart has a larger potential for adaptive hypertrophic 
growth than that of mammals. We did not observe any significant increase in RCAN1 mRNA 
levels after 21 days of cortisol treatment in this study. RCAN1 levels were not increased after 
45 days of cortisol treatment either (Johansen et al. unpublished).  
Interestingly, we found a trend towards increased RCAN1 mRNA levels in fish 
administered both antagonists, a tendency that was also present although to a smaller extent, 
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in fish that were administered the GR antagonist alone. Although speculative, it could be that 
when both receptors are transactivationally active interaction between the two results in a 
different expression from when only one receptor is active. Thus, when GR is blocked, MR-
activation might result in other genes being activated.    
4.4 Vascularization 
Cardiac hypertrophy is often accompanied by increased vascularization to meet the higher 
metabolic demand of the growing tissue. We did not find any significant increase in mRNA 
abundance of the angiogenesis marker VEGF after 21 days of cortisol treatment. VEGF 
mRNA levels were not increased after 45 days of cortisol treatment either (Johansen et al. 
unpublished). In HR fish, extensive vascularization was observed upon visual examination of 
the hearts and VEGF was much higher expressed than in LR hearts (Johansen et al., 2011). 
Our results do not indicate that there is any substantial vascularization after 21 days of cortisol 
treatment. It is possible that increased vascularization occurs at a later point of the heart 
growth. However, if the observed heart growth is not accompanied by increased 
vascularization, inadequate blood supply could impair cardiac function.  
4.5 Collagen and fibrosis 
Cardiac hypertrophy is often accompanied by fibrosis, which is an increase in myocardial 
collagen concentration (Weber et al., 1994). In healthy individuals the fibrillar collagen 
network serves an elastic element in the heart but the presence of fibrosis adversely enhances 
myocardial stiffness and impairs normal cardiac function (Swynghedauw, 1999).  
Collagen mRNA levels were reduced by cortisol treatment both after 21 days and a 
similar reduction was observed after 45 days of cortisol treatment (Johansen et al. 
unpublished). In cold-induced cardiac hypertrophy collagen mRNA levels were reduced 5-
fold (Vornanen et al., 2005). In HR fish, collagen mRNA levels were however increased and 
staining for collagen deposition revealed conditions similar to pathological focal fibrosis in 
mammals (Johansen et al., 2011). The collagen network has been postulated to play an 
important role in cardiac mechanical performance in fish (Icardo et al., 2005) and increased 
collagen network appears to be implicated in improved cardiac performance (Cerra et al., 
2004). Lower collagen mRNA levels may reflect reduced collagen deposition. What 
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consequences reduced mRNA collagen deposition could have on the elasticity of the rainbow 
trout heart is uncertain.  
Although we did not find any sign of fibrosis at the mRNA level, we cannot rule out 
that fibrosis was present. It is possible that low collagen mRNA levels reflect a high level of 
translation into protein and subsequent mRNA degradation. In that case there could be 
fibrosis although the mRNA levels were low. Histochemical staining for collagen depositions 
will be a next step in characterizing the hearts and determining if they show signs of fibrosis.  
Interestingly, the effect of cortisol on collagen mRNA levels was blocked by treatment 
with the GR antagonist. In humans and animal models, the presence of excess aldosterone in 
the blood (hyperaldosteronemia) is correlated with cardiac fibrosis when combined with a 
high salt intake (Rossier, 2008). Aldosterone in combination with a high salt diet induces 
fibrotic responses in the hearts of rats that have had one kidney surgically removed (Rossier, 
2008) and stimulates collagen synthesis in cultured adult rat cardiac fibroblasts (Brilla et al., 
1994). In both cases, the response is blocked by MR antagonists including spironolactone. It 
is surprising and interesting if cortisol has the opposite effect of aldosterone on cardiac 
fibroblasts and that this effect is mediated through the cardiac GR.   
4.6 Natriuretic peptides and heart failure 
In mammals, the natriuretic peptides ANP and BNP are sensitive markers of heart failure. The 
mRNA levels of ANP, BNP and an additional form which is present in fish called VNP, were 
investigated to see if the hearts showed signs of pathological cardiac remodeling. However, 
the long-term effects of NPs on heart growth and remodeling in fish are not known (Tota and 
Cerra, 2009) and NPs may have other functions and be differently regulated in fish than in 
mammals (Loretz and Pollina, 2000). We did not find any significant increase in ANP, BNP 
or VNP mRNA after 21 days of cortisol treatment. ANP and VNP were however increased 
after 45 days of cortisol treatment (Johansen et al. unpublished). If we assume that natriuretic 
peptides are up-regulated in fish in the same way as in mammals during heart failure, these 
result indicate that the cortisol-treated fish hearts are not failing at this time point.  
4.7 Cortisol receptors 
The mRNA levels of the different cortisol receptors were not significantly changed in this 
study or after 45 days of cortisol treatment (Johansen et al. unpublished). This is unexpected 
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as an inverse relationship between cortisol levels and the number of GR receptors has been 
reported for many tissues (Mommsen et al., 1999). GR mRNA and protein are mainly 
homologously regulated (Mommsen et al., 1999), which suggests that our results on the 
mRNA level of GR are representative of the protein level.  
We did not find the mRNA abundance of the three receptors to be affected by the 
administration of antagonists either. Recently, it was shown that mifepristone (without 
exogenous cortisol treatment) caused a suppression of GR protein in rainbow trout liver, 
brain, preoptic area and head kidney by reducing protein expression (by 40-75%) (Alderman 
et al., 2012). This suppression of protein levels corresponded with an up-regulation of GR 
mRNA levels. This was however after a short time period (3 days) of treatment with 
mifepristone only and a subsequent stressor application. It is likely that differences in 
methodology or time point is responsible for the discrepancy between these and our results. 
For example, the suppression of GR was observed after only 3 days. In contrast, we gave 
exogenous cortisol and antagonist over a long time period. 
The concentration of cortisol receptors is a limiting factor in the sensitivity of a tissue 
to cortisol (Vanderbilt et al., 1987; Dong et al., 1989). Since both MR and the two GRs are 
normally abundantly expressed in cardiac tissue of fish and the mRNA levels of the three 
receptors were similar to that of the controls, we can assume that the cardiac tissue of cortisol-
treated fish was still susceptible to cortisol stimulation. 
4.8 Methodological considerations 
4.8.1  The use of mifepristone (RU486) and spironolactone  
Mifepristone is well established as a means to block GR in fish studies. The antagonist has 
been shown to bind GR with high affinity in several fish tissues (Lee and Bols, 1989; 
Pottinger, 1990) and was evaluated by Mommsen et al. (1999) to be an excellent experimental 
tool for blocking GR-induced activities in fish systems. In the present study, the observed 
effects of mifepristone on feed intake, growth rate and collagen mRNA levels indicate that it 
was working.  It did however not completely block the effect of cortisol in any of these cases 
which indicates that it was not working optimally or alternatively that the MR was 
compensating when GR antagonist was administered alone. Although mifepristone is a potent 
GR antagonist in most cases it appears that it has agonist effects on some genes (Mommsen et 
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al., 1999), we can therefore not exclude that some of the effects we saw of mifepristone were 
agonistic effects.    
We did not observe any antagonistic effect of spironolactone in this study. This does 
however not rule out that the cardiac MR is involved in mediating the effect of cortisol on the 
processes under investigation. Spironolactone has only recently been used to study the 
possible functions of the MR in fish (Sloman et al., 2001; Schjolden et al., 2009) and to our 
knowledge, it has not before been used to investigate the functions of the cardiac MR. The 
anti-mineralocorticoid effects of spironolactone in fish are not so well documented and here is 
a lack of information about its binding and specificity to teleost corticosteroid receptors 
(Sturm et al., 2005). In a mammalian cell line expressing rainbow trout MR, Sturm et al. 
(2005) found spironolactone to have agonist activity. If that is the case, then we may not 
observe any differences between fish treated with cortisol only and fish treated with 
spironolactone in combination with cortisol.  
It is also possible that the antagonists were not working as efficiently as they could 
have due to insufficient doses and different stabilities of cortisol and the antagonists. For 
instance, cortisol has a longer half-life than spironolactone. Barton et al. (1987) showed that 
long-term cortisol treatment increases the clearance rate of cortisol in fish but still cortisol 
plasma levels remain elevated for about 24 hours following feeding. Plasma cortisol levels 
peaked about 3 hours after administration. In humans, spironolactone is metabolized at a 
much faster rate than cortisol. A dose of 100 mg spironolactone reaches a peak concentration 
within about 1 hour of administration and is not traceable in plasma after 10-11 hours (Vlase 
et al., 2011). Serum mifepristone also peak about 1 hour after administration, but in contrast 
to spironolactone, it has a long half-life which is dose dependent (Cadepond et al., 1997). 
However, Cadepond et al. (1997) pointed out that the tissue blockage of cortisol by 
mifepristone might be of short duration. Although the stability of spironolactone and 
mifepristone might be different for fish, this information indicates that the cortisol receptors 
might only have been blocked for a limited time after each meal leaving considerable time for 
cortisol to freely access its receptors. In hindsight, we realize that a pilot experiment should 
have preceded our antagonist study in order to establish appropriate doses and administration 
time points for the antagonists. This would also have allowed us to identify possible positive 
controls (known targets of the different cortisol receptors) that could be used in our 
experiment to verify the function of the antagonists. 
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4.8.2  Plasma cortisol levels 
The main intention for measuring plasma cortisol was to verify that cortisol-treated fish had 
elevated cortisol levels. Of note, blood samples were taken 24 hours after the last feeding and 
because of the observed variation in feed intake, individual plasma cortisol levels does not 
necessarily represent the average cortisol exposure of that particular fish. Plasma cortisol 
levels of unstressed fish have been reported to range from 2-42 ng/ml  (Gamperl et al., 1994) 
while others report it to be <5 ng/ml (Wendelaar Bonga, 1997). Plasma cortisol levels ranged 
from 0.20 to 9.73 ng/ml in the time-course experiment (four control fish had values above 5 
ng/ml), and from 0.19 to 0.60 ng/ml in the antagonist experiment. Thus, most control fish 
showed plasma cortisol levels well within the range of normal unstressed values. 
Administration of cortisol in the feed resulted in elevated plasma cortisol levels 24 hours after 
the last feeding. Plasma cortisol levels after 2 days of cortisol treatment were remarkably high 
(433.30 ± 101.5 ng/ml) and significantly higher than after 7 and 21 days of cortisol treatment 
(86.79 ± 28.18 ng/ml and 89.62 ± 25.72 ng/ml, respectively). This is likely the result of a high 
feed intake during the first days of treatment as it took a couple of days for the suppressive 
effect of cortisol on feed intake to set in.   
Administration of both receptor-antagonists in combination with cortisol and of the 
GR antagonist in combination with cortisol, resulted in higher plasma cortisol levels 24 hours 
after last feeding than in fish treated with cortisol only (397.40 ± 90.14 ng/ml versus 133.70 ± 
40.57, respectively). Administration of the MR antagonist together with cortisol did not have 
this effect. This suggests that the GR antagonist was responsible for the increase in plasma 
cortisol concentration. Some of the elevation in plasma cortisol concentrations may be 
explained by the fact that GR antagonist-treated fish ate more and thereby ingested more 
cortisol than fish that got only cortisol. In humans, mifepristone eliminates the negative 
feedback control of cortisol on the HPA-axis, resulting in increased ACTH release and 
cortisol secretion (Cadepond et al., 1997). If this is the case for fish as well then the observed 
increase in plasma cortisol in mifepristone treated fish may also in part be due to production 
of endogenous cortisol. Therefore it might be a combination of a higher feed intake and 
inhibition of the negative feedback by cortisol on the HPA-axis that lead to the strikingly high 
cortisol concentration observed in GR antagonist-treated fish. 
Cortisol levels during stress vary greatly depending on the stressor (20-500 ng/ml) but 
are commonly <300 ng/ml (Gamperl et al., 1994). The cortisol levels after 2 days of cortisol 
treatment and after treatment with GR antagonist in combination with cortisol bordered to the 
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supraphysiologcal and might therefore not be representative of a physiological state. In rare 
cases physiological cortisol levels can be extremely high. An intriguing example of this is the 
extremely high levels of cortisol found in Pacific salmon after spawning. In these fish the 
negative feedback system breaks down and cortisol excess has been shown to be directly 
responsible for their death (Sapolsky, 2004). 
4.8.3  Oral administration versus other modes of cortisol administration 
The main methods for long-term administration of cortisol are either to incorporate it into the 
diet, like in the present study, or to administer it repeatedly by injections or through implants. 
There are several advantages of administering cortisol orally. Oral delivery of cortisol 
requires no anesthetic, handling or surgical procedures. Handling, anesthesia and surgery can 
cause alterations in several physiological parameters including plasma catecholamines and 
lactate levels (Gamperl et al., 1994) and make it difficult to discern whether the observed 
effects are due to elevated cortisol levels or something else. Moreover, sham treatment 
(injection of for example saline but without hormone) of controls is necessary in order to 
control for possible effects of such handling. If the handling is stressful, then this will result in 
undesired endogenous cortisol release in the control fish.  Furthermore, orally administered 
cortisol is digested and absorbed without destruction and after a few days we see plasma 
cortisol levels that are comparable to physiological levels during stress. One of the 
disadvantages of administering cortisol through the feed is, however, that we cannot control 
how much cortisol each individual ingests. Nevertheless, previous findings indicate that it is 
not the absolute dose of cortisol which is important for it to exert its effects (as long as it is 
above control levels) but rather the duration of the treatment. Oral administration of cortisol at 
low (75 mg/kg feed) and high cortisol doses (600 mg/kg feed) for 6 days had 
indistinguishable effects on cell proliferation in the telencephalon of rainbow trout (Sørensen 
et al., 2011). Still, in order to get an indication of how much feed the fish were consuming, we 
monitored feed intake and body weight. 
4.8.4 Body weight, growth rate and feed intake 
Cortisol treatment for 21 days reduced the growth rate of fish in both experiments. In the 
time-course experiment the body weight was measured before the acclimation period. Since 
the experimental fish are likely to have gained weight in this period it is possible that the 
differences in growth rate between cortisol treated fish and their controls were 
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underestimated. Several studies have shown that cortisol reduces growth rates in fish (Davis 
et al., 1985; Barton et al., 1987). The mechanisms by which cortisol suppresses growth are not 
fully understood but several explanations have been suggested. Barton et al. (1987) reported 
that cortisol administration in the feed affected gut morphology and suggested that this could 
result in poorer absorption of food. Such alterations to gut morphology were reported after 
cortisol elevation by implants (Robertson et al., 1963; McBride and van Overbeeke, 1971) 
and after chronic stress (Peters, 1982) in several teleost species. Davis et al. (1985) suggested 
that elevated plasma cortisol might shift metabolism towards protein catabolism and that this 
may result in reduced growth. 
Both these mechanisms probably contribute to the reduced growth rate observed in the 
current experiment. In addition, we propose that a considerable part of the reduction in growth 
rate of cortisol-fed fish in this study was due to the negative effect of cortisol on feed intake. 
In both experiments a reduction in feed intake was observed visually and confirmed 
statistically. In many studies where cortisol administration reduced growth rates, information 
on feed intake is lacking. Barton et al. (1987) reported a loss of appetite in cortisol-treated fish 
although all feed was eaten. Gregory and Wood (1999) found that feed intake was 
significantly reduced in cortisol-treated fish. They attributed this to a reduced appetite in these 
fish. Our impression from observing the feeding behavior of cortisol-treated fish was not that 
their appetite was reduced. In fact, the fish were actively seeking the pellets and attempting to 
ingest them while moving their jaws vigorously. The pellets were taken by the fish, but after 
several attempts of ingesting them they eventually spit them out.   
To rule out the possibility that the fish rejected the pellets because they could taste the 
cortisol, normal untreated pellets were presented to the cortisol-treated fish. The same spitting 
behavior was observed, indicating that the fish do not reject the pellets because they taste of 
cortisol. Moreover, during the first few days of cortisol-treatment, the fish ingested the 
cortisol-containing pellets normally. We speculate that cortisol affects either muscle tissue in 
the jaw/throat or inhibits nerves controlling the swallowing making it difficult for the fish to 
ingest the pellets.  
In mammals, loss of feedback inhibition of the HPA-axis has been shown to suppress 
appetite because more CRH, which is an inhibitor of appetite, is produced (Heinrichs and 
Richard, 1999). Instead we observe that fish treated with the GR antagonist mifepristone 
(which is known to eliminate this negative feedback at least in mammals) in combination with 
cortisol eat approximately the same amount of feed as the controls. Treatment with cortisol 
and both antagonists did however not result in a significantly higher feed intake. This 
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discrepancy could be a result of the antagonists not working optimally or because the MR 
antagonist repressed the effect of the GR antagonist in some way. 
Quite unexpectedly, we may now be about to unravel the mechanism behind reduced 
feed intake in stressed fish. The spitting behavior that we observe in cortisol-treated fish is a 
behavior we and others recognize from previous studies in which stressed fish struggle to eat. 
For example, juvenile Chinook salmon, stressed by high density confinement, refused food 
and subsequently grew less (Swynghedauw, 2006). Also HR fish, which respond to stressors 
with high levels of cortisol, tend to regain feed intake slower than LR fish when transferred to 
a new environment (Øverli et al., 2005). The results from our current study strongly indicate 
that  such feeding inhibition is most likely a direct effect of the stress hormone cortisol and, 
importantly, that this effect of cortisol is mediated through the GR. Low feed intake and 
reduced growth rates is also a well-known problem for the aquaculture industry. Our findings 
may thus have important implications for the aquaculture industry and their practices.  
4.8.5 What can mRNA tell us? 
An assumption for studying mRNA levels indicative of expression is that it is an informative 
predictor of protein expression. Translational and post-translational modifications can 
however limit this relationship. For example reductions in mRNA levels do not necessarily 
mean reduced gene activity but might be contributed to enhanced degradation of mRNA 
transcripts. We can thus not rule out that for some of the genes under investigation, mRNA 
levels might not give a good picture of what was going on at the protein level. A recent study 
in mammalian cells does however indicate that mRNA levels correlate better with protein 
levels than what was previously thought (Schwänhausser et al., 2011) but knowledge about 
the regulation of mRNA translation to protein is poorer for fish.  
For some of the cardiac marker genes investigated (RCAN1 and the natriuretic 
peptides) however, the direct aim was to detect changes in mRNA expression. Changes in 
mRNA levels of RCAN1 serve as a direct measure of NFAT activity because RCAN1 is a 
direct target gene of NFAT. The mRNA levels of the natriuretic peptides and heart failure 
markers ANP and BNP are mainly quantified by qRT-PCR both in the clinic and in 
experimental models associated with hypertrophy (Gardner, 2003).  
For many of the genes investigated, it would however have been informative to 
measure both mRNA and protein levels. Unfortunately, specific antibodies for rainbow trout 
(or closely related species) are not commercially available making it time consuming and/or 
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expensive to perform protein analysis. Future work should nevertheless aim at investigating 
gene activity both at the transcriptomic and proteomic level. The optimal gene expression 
analysis would be to measure both absolute mRNA and protein abundance and turnover 
simultaneously in the same sample. This has recently been done on a genome-wide scale in 
mammalian cell lines by the use of pulse labeling with radioactive nucleotides or amino acids 
(Schwänhausser et al., 2011).  
4.9 Future perspectives 
Although we have strong indications that the hearts are growing mainly through hypertrophy, 
we cannot rule out that part of the increase in ventricle weight can be due to other factors such 
as an increase in water content or in extracellular matrix. We have therefore fixed hearts from 
the antagonist experiment, of which histochemically stained sections can be used to 
investigate the size and shape of single cardiomyocytes. Since we have indications that the 
antagonists were not working optimally and since it is possible that the MR antagonist was 
not working at all, it would be of interest to repeat the antagonist study perhaps with a 
different MR antagonist. One obvious candidate is eplerenone, which is a selective MR 
antagonist emerging as an alternative to spironolactone in human medicine. Eplerenone has a 
lower affinity for MR than spironolactone, but a greater specificity in that it has a very low 
affinity for other steroid receptors (Ho et al., 1993). As mentioned previously, a pilot study 
could identify the usefulness of different MR antagonists. The doses of cortisol and 
antagonists and the time-points of feeding should be modified to ensure that the cortisol-
receptors are blocked continuously. In hind sight, we also realize that we profitably could 
have blocked the cortisol receptors for longer than 21 days as several cardiac markers (MLP, 
ANP and VNP) were up-regulated after 45 days, but not after 21 days. In a new attempt to 
investigate receptor-specific effects of cortisol on heart remodeling it would thus be of interest 
to prolong the antagonist experiment to 45 days.  
Johansen et al. (unpublished) demonstrated that rainbow trout treated with cortisol for 
90 days had significantly poorer swimming performance than the controls, which indicates 
reduced cardiac function Still, a next step in characterizing the heart growth as either 
pathological or physiological will be to directly investigate cardiac function. One approach to 
this is to measure maximum cardiac performance in an in situ perfused heart preparation or by 
echocardiography. Furthermore, it would be interesting to determine whether the heart growth 
is reversible if cortisol administration is terminated and the fish allowed to recover.  
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4.10 Summary and conclusions 
The high plasticity of the salmonid heart combined with the large size of the animals 
which allow for the examination of phenotypic changes, makes salmonid fishes good models 
for investigating some aspects of cardiac remodeling. The time-course experiment revealed a 
steep growth phase of the hearts around 21 days. There was a striking, although not 
significant, increase in relative ventricle weight after only 2 days of cortisol treatment (19% 
increase in CSI). However, the heart growth was not so conspicuous after 7 days of cortisol 
treatment (8% increase in CSI).  
In the antagonist experiment, we found that 21 days of oral administration of cortisol 
induces a 20% increase in relative ventricle weight in rainbow trout and this was accompanied 
by up-regulation of the hypertrophy markers VMHC and SMLC2, indicating that the heart is 
growing through hypertrophy. In mammals, these are markers of heart disease. We can 
however not conclude that they have the same function in fish. Interestingly, we found lower 
mRNA levels of markers of collagen synthesis, COL1α1 and COL1α2 and of the cell 
proliferation marker PCNA in cortisol-treated fish compared to controls. Markers of heart 
failure, ANP and BNP, and the fish specific natriuretic peptide VNP, the angiogenesis marker 
VEGF and the marker of pathological cardiac remodeling RCAN1 were not up-regulated in 
cortisol-treated fish. Thus, considering the overall gene transcript profile for the cardiac 
markers there were no clear indication of heart disease at this time point. The mRNA levels of 
the cardiac cortisol-receptors (MR, GR1 and GR2) were unchanged in cortisol-treated fish 
compared to controls, indicating that cortisol-treated fish were susceptible to cortisol stimuli. 
Cortisol mediates its effects mainly through cortisol receptors and it should therefore 
be possible to block the effect of cortisol by the use of receptor antagonists. Unfortunately, we 
were not able to block the cortisol-induced heart growth by administering cortisol receptor 
antagonists in combination with cortisol. We were, however, able to block the suppressive 
effect of cortisol on COL1α1 and COL1α2 mRNA levels, feed intake and growth rate by use 
of the GR antagonist mifepristone. We also got some indication that the suppression of PCNA 
mRNA levels was mediated through the GR. Altogether, this indicates that the GR antagonist 
was working and, more importantly, that GR mediates the effects of cortisol on these targets.  
During the course of the experiment we discovered an unexpected but intriguing effect 
of cortisol on the fish. Cortisol inhibited feed intake by an apparent hindering of pellet 
swallowing and ingestion of feed. Further, this effect was blocked by the GR antagonist 
mifepristone. This finding will certainly be pursued further. Whether it is appetite, muscle 
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tissue in the jaw/throat or nerves controlling swallowing that are affected by cortisol, remains 
to be determined. Nevertheless, this finding may have important implications for the 
aquaculture industry where low feed intake and subsequent low growth rate is commonly 
observed in a subset of individuals.  
In conclusion, we show that cortisol treatment for 21 days induces a 20 % increase in 
relative ventricle weight and is accompanied by up-regulation of several markers of 
cardiomyocyte hypertrophy, but not of hyperplasia. In mammals, these are markers of heart 
disease. We can however not conclude that they have the same function in fish. Future work 
should aim at determining whether the cardiac function of cortisol-treated fish is impaired. A 
new antagonist experiment should be performed in order to determine which receptors are 
mediating the heart growth. The involvement of the MR in inducing cardiac remodeling in 
salmonids thus remains to be clarified.  
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5 APPENDICES 
5.1 Appendix A: Supplementary description of methods  
5.1.1 RNA extraction and quantitative real time-PCR analysis 
Isolation of total RNA using TRIzol Reagent 
Upon RNA extraction the ventricles that were stored on RNAlater at -20˚C were thawed and 
removed from the RNAlater solution. Excess RNAlater was gently dried off using lens paper 
and the ventricles were weighed. Total RNA was extracted from the ventricles using TRIzol 
reagent (Invitrogen, Life Technologies, Carlsbad, CA, USA) according to the manufacturer’s 
protocol. Extractions were performed in random order. The tissue samples were homogenized 
in Trizol reagent at a ratio of 15 µl TRIzol per mg tissue using an IKA Labortechnik T25 
basic electrical homogenizer (IKA®-Werke GmbH & Co. KG, Staufen, Germany) and 
incubated at room temperature for 10 minutes. 1000 µl homogenate was transferred to RNase-
free eppendorf tubes. 200 µl chloroform was added and the samples were thoroughly mixed 
by shaking. The samples were incubated for 5 minutes at room temperature and subsequently 
centrifuged for 15 minutes (4˚C, 10 000 rpm). 400 µl of the RNA containing aqueous phase 
was carefully transferred to a new tube avoiding contamination from the intermediate layer.  
The RNA was precipitated by mixing with 400 µl nuclease-free isopropanol, incubating the 
samples for 10 minutes at room temperature and thereafter for 30 minutes at -20˚C. The latter 
step was performed as this has been shown to give a higher yield of RNA. The samples were 
centrifuged for 10 minutes (4˚C, 10 000 rpm) to pellet the RNA. The supernatant was 
removed and the pellet washed twice with 500 µl 75% ice-cold ethanol (made with DEPC-
water) and centrifuged for 5 minutes (4 ˚C, 8 000 rpm) after each application of ethanol. 
When the second round of ethanol had been removed, the pellet was centrifuged for 1 minute 
(4 ˚C, 8 000 rpm) to spin down any remaining ethanol and as much ethanol as possible was 
removed with careful pipetting. The RNA pellet was air-dried until it had just turned 
transparent or for a maximum of 10 minutes. Subsequently, the RNA was re-suspended in 30 
µl RNA Storage Solution (Ambion, Life Technologies) by repeatedly pipetting the solution 
over the pellet and incubating for 10 minutes at 50˚C.  After 5 minutes of incubation the 
contents was mixed by flickering the tubes. 
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DNase treatment 
The RNA (30 µl)  was treated with 2 µl DNase using the TURBO DNA-free Kit (Ambion, 
Life Technologies) to remove contaminating DNA from the RNA preparations and 
subsequently remove DNase and divalent cations from the sample. Turbo DNA-free buffer 
and Turbo DNase were added to the samples which were then incubated for 30 minutes at 
37˚C. Turbo DNase inactivation reagent was added and mixed well with the contents by 
repeated pipetting and by flickering the tubes. The samples were incubated with inactivation 
reagent for 2 minutes in room temperature and centrifuged for 1.5 minutes (4°C, 10 000 rpm) 
to pellet the DNase Inactivation reagent. After centrifugation the supernatant was carefully 
transferred to a new tube. 
The purified RNA was quantified using the NanoDrop ND-2000 UV-Vis 
Spectrophotometer (Thermo Fisher Scientific Inc., Wilmington, DE, USA). It measures the 
absorbance of the sample at 260 and 280 nm and determines the concentration of nucleic 
acids using Beer-Lambert’s law which predicts a linear change in absorbance with 
concentration. RNA quality was confirmed using the 2100 Bioanalyzer (Agilent Technologies 
Inc., Santa Clara, CA). The software uses an algorithm to calculate a RNA integrity number 
(RIN) for each sample. The RIN score ranges from 1 to 10, where level 10 RNA is completely 
intact. 
cDNA synthesis 
Total RNA was reverse transcribed into cDNA using oligo(dT)18-20 primers (Invitrogen) and 
the SuperScript III Reverse Transcriptase Kit (Invitrogen). Reverse transcription was 
performed on 2 µg RNA using oligo(dT)18-20  primers (500 ng/ml) and dNTP mix (10mM of 
each). These reagents were incubated together with RNA for 5 minutes at 65°C and held on 
ice for one minute. Subsequently, RNase free-water, 5x-First Strand Buffer, DTT (0.1M) and 
SuperScript III RT (200U/µl) was added and mixed by pipetting and spun down at room 
temperature for 1 second. Total RNA was reverse transcribed using a Mastercycler gradient 
thermal cycler (Eppendorf AG, Hamburg, Germany) with incubation for 60 minutes at 50°C 
followed by inactivation for 15 minutes at 70°C. The resulting cDNA was diluted to the 
concentration used in qRT-PCR (25x dilution) by adding autoclaved MilliQ water.  
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Quantitative real-Time PCR  
Quantitative real-time PCR (qRT-PCR) reactions were performed with the LightCycler480 
Real-Time PCR System (Roche Diagnostics, Basel, Switzerland), using the LightCycler 480 
SYBR Green 1 Master mix (Roche Diagnostics) with 3 µl 1:25 diluted cDNA, 5 µM SYBR 
Green 1 Master mix, 1 µl each primer (forward and reverse primer, each 100nM), for a total 
reaction volume of 10 µl. All reactions were run in duplicates on different plates.  
Real-time PCR was run using the following program: Incubation for 10 min at 95°C, 
42 cycles of PCR with each cycle consisting of DNA denaturation for 10 seconds at 95°C, 
primer annealing for 10 seconds at 60 °C, DNA polymerase mediated DNA replication for 10 
seconds at 72°C. The specificity of the primers was verified by the generation of a melting 
curve from a steady rise in temperature from 65°C to 97°C. The program ended with cooling 
for 10 seconds at 40°C. 
5.1.2 Radioimmunoassay quantification of plasma cortisol 
Plasma cortisol was analyzed using a radioimmunoassay based on the assay by Pottinger and 
Carrick (2001). Ethyl acetate (Merk Chemicals, Darmstadt, Germany) was added to plasma 
(1:5 plasma:ethyl acetate) to extract cortisol. The samples were vortexed for 3 x 5 seconds 
and centrifuged for 2 minutes at 14 000 rpm. Depending on the expected cortisol levels of the 
fish, 5-150 µl of extract was transferred to 1.5 ml eppendorf tubes. A diluted series standard 
curve was constructed by adding to a series of tubes aliquots of ethyl acetate containing 
between 12.5 and 800 pg of inert cortisol (hydrocortisone, Sigma). A zero sample and a 
control for non-specific binding (blank) were made with pure ethyl acetate. All samples, 
standards and controls were run in duplicate. 50 µl aliquots containing approximately 16 000 
cpm of [1,2,6,7-3H] cortisol (Amersham Pharmacia Biotech, Little Chalfront, UK, 60 Ci 
mmol-1) was added to all tubes. Subsequently, the ethyl acetate was evaporated in an 
exsiccator coupled to a water-jet pump. 200 µl of donkey anti-cortisol antibody (AbD Serotec, 
Dusseldorf, Germany) in assay buffer (1:600 dilution); phosphate-buffered saline (PBS 
tablets, Sigma) containing bovine serum albumine (0.1%, Sigma), was added to each tube 
except the blank tubes which received only assay buffer. The tubes were shaken on an orbital 
shaker for 10 minutes at 4°C and incubated for 18 hours or more at 4°C. After incubation, the 
tubes were put on ice and 100 µl of cold, stirred dextran-coated charcoal in PBS (1.0% 
activated charcoal, Sigma ; 0.2% dextran, Sigma) was added to each tube which were held on 
ice. The tubes were vortexed, incubated for 10 minutes at 4°C and centrifuged for 10 minutes 
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(4°C, 8000 rpm). Dextran-coated charcoal absorbs free cortisol leaving hormone that is bound 
to antibody in the supernatant. 200 µl of supernatant from each tube was transferred to 
scintillation vials containing 4 ml scintillation fluid (Ultima Gold, Perkin Elmer, Waltham, 
MA, USA), mixed by vortexing and counted on a Packard Tri-Carb A1900 TR liquid 
scintillation analyzer (Packard Instrument, Meriden, CT, USA). A 3-parameter hyperbolic 
funtion was fitted to the plot of the percentage of 
3
H-cortisol bound against cortisol 
concentration in the standard curve samples using SigmaPlot 11(SPSS Science, Systat 
Software Inc., San Jose, CA, USA. The equation from this function was used to estimate the 
cortisol concentration in the unknown samples. The amount of of extract analysed was 
corrected for when the plasma cortisol levels were calculated. 
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5.2 Appendix B: Supplementary tables 
 
Table 4 Physiological data for study animals in the time-course experiment 
 Control 2d Cortisol  
2d 
Control  
7d   
Cortisol  
7d 
Control  
21d 
Cortisol  
21d 
N of fish 7 8 8 8 7 7 
Heart weight (g) 135.3 ± 12.3 167.0 ± 9.1 156.7 ± 5.3 157.5 ± 13.5 216.8 ± 18.7 185.6 ± 21.6 
Body weight end 176.1 ± 10.2 187.0 ± 11.1 196.4 ± 9.1 179.8 ± 8.5 233.2 ± 18.0 177.3 ± 14.6 
CSI (g vw/g bw 
x10
3
) 
0.7626 ± 
0.0490 
0.9049 ± 
0.0465 
0.8034 ± 
0.0320 
0.8704 ± 
0.0464 
0.9291 ± 
0.0394 
1.042 ± 
0.0606 
Plasma cortisol 
(ng/ml) 
3.30 ± 1.42 433.30±101.
5 
3.60 ± 1.19 86.79±28.18 0.80 ± 0.44 89.62 ± 25.72 
Data are presented as mean ± s.e.m 
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Table 5 Physiological data for study animals in the antagonist experiment 
 Control Cortisol Cortisol + 
MR+ GR   
Cortisol + 
MR 
Cortisol + 
GR 
N of fish 16 16 16 15 16 
Heart weight (g) 215.9 ± 9.9 205.7 ± 
11.2 
224.0 ± 9.1 193.7 ± 
12.9 
227.3 ± 
11.7 
Body weight 276.8 ± 10.6 219.1 ± 
11.5 
237.4 ± 8.7 216.8 ± 
10.9 
247.0 ± 
10.1 
CSI (g vw/g bw x10
3
) 0.7828 ± 
0.0260 
0.9427 ± 
0.0267 
0.9484 ± 
0.0295 
0.8869 ±  
0.0241 
0.9190 ± 
0.0276 
CSI % relative to control 100.00±3.32 120.4±3.41 121.2±3.77 106.2±7.65 117.4±3.53 
Plasma cortisol (ng/ml) 0.25 ± 0.05 133.70± 
40.57 
474.80 ± 
75.25 
146.90 ± 
81.69 
397.40 ± 
90.14 
Cardiomyocyte hypertropy 
Relative mRNA abundance of 
VMHC  
1.00 ± 0.04 1.49 ± 0.09 1.44 ± 0.07 1.44 ± 0.06 1.43 ± 0.09 
Relative mRNA abundance of 
SMLC2 
1.00 ± 0.16 4.13 ± 0.96 3.62 ± 0.66 4.38 ± 1.12 4.83 ± 0.89 
Relative mRNA abundance of MLP  1.00 ± 0.14 0.69 ± 0.08 0.98 ± 0.15 0.70 ± 0.09 1.10 ± 0.15 
Relative mRNA abundance of α-
actin 
1.00 ± 0.05 1.15 ± 0.08 1.26 ± 0.10 1.05 ± 0.06 1.20 ± 0.08 
Cell proliferation 
Relative mRNA abundance of 
PCNA 
1.00 ± 0.12 0.33 ± 0.01 0.56 ± 0.03 0.37 ± 0.03 0.46 ± 0.05 
Pathological cardiomyocyte hypertrophy 
Relative mRNA abundance of 
RCAN1 
1.00 ± 0.08 1.21 ± 0.09 1.34 ± 0.11 1.03 ± 0.09 1.31 ± 0.10 
Vascularization 
Relative mRNA abundance of VEGF 1.00 ± 0.10 1.24 ± 0.10 1.28 ± 0.10 1.34 ± 0.13 1.29 ± 0.10 
Collagen/fibrosis 
Relative mRNA abundance of 
COL1α1 
1.00 ± 0.05 0.57 ± 0.05 0.80 ± 0.06 0.50 ± 0.04 0.86 ± 0.07 
Relative mRNA abundance of 
COL1α2 
1.00 ± 0.08 0.53 ± 0.04 0.79 ± 0.05 0.48 ± 0.06 0.84 ± 0.07 
Natriuretic peptides  
Relative mRNA abundance of ANP 1.00 ± 0.07 1.14 ± 0.12 1.19 ± 0.07 1.16 ± 0.10 1.14 ± 0.10 
Relative mRNA abundance of BNP 1.00 ± 0.07 0.72 ± 0.13 1.11 ± 0.13 0.75 ± 0.19 0.66 ± 0.10 
Relative mRNA abundance of VNP 1.00 ± 0.07 1.06 ± 0.12 1.27 ± 0.07 1.10 ± 0.11 1.33 ± 0.12 
Corticosteroid receptors 
Relative mRNA abundance of MR 1.00 ± 0.04 0.92 ± 0.07 1.02 ± 0.10 0.84 ± 0.07 1.12 ± 0.08 
Relative mRNA abundance of GR1 1.00 ± 0.05 0.98. ± 0.08 1.10 ± 0.07 0.97 ± 0.08 1.13 ± 0.05 
Relative mRNA abundance of GR 2 1.00 ± 0.07 1.02 ± 0.07 1.17 ± 0.13 1.07 ± 0.09 1.10 ± 0.11 
Data are presented as mean ± s.e.m. All data on mRNA abundance is relative to β-actin and are presented 
relative to control mRNA levels. Body weight and heart weight was calculated for each group from the mean of 
16 animals. The ventricles of 12 fish from each group was used for analysis of mRNA abundance.  
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Table 6 Summary of ANOVA statistics for the antagonist experiment  
 F 
statisit
c 
P 
statistic 
CONT 
vs 
CORT 
CONT 
vs 
CORT+
BA 
CONT 
vs 
CORT+ 
MR 
CONT 
vs 
CORT+ 
GR 
CORT 
vs 
CORT+ 
BA 
COR
T vs 
COR
T 
+MR 
COR
Tvs 
COR
T+GR 
CORT+
BA 
vs 
CORT+ 
MR 
CORT+
BA vs 
CORT+
GR 
CORT+ 
MR vs 
CORT+ 
GR 
VMHC  7.05 0.0001 0.0003 0.0014 0.0012 0.0018 0.99 0.99 0.98 > 0.99 > 0.99 >0.99 
SMLC2  7.95 <0.0001 0.0006 0.0031 0.0007 <0.0001 0.98 >0.99 0.97  0.99 0.76 0.95 
MLP  2.23 0.08 0.43 > 0.99 0.44 0.98 0.47 >0.99 0.17 0.48 0.97 0.17 
α-actin 1.64 0.18 0.65 0.23 0.99 0.33 0.95 0.90 0.98 0.49 >0.99 0.62 
PCNA 22.85 <0.0001 <0.0001 0.03 <0.0001 <0.0001 <0.0001 0.86 0.06 0.0007 0.13 0.39 
RCAN1 2.75 0.04 0.53 0.09 >0.99 0.14 0.85 0.70 0.93 0.17 >0.99 0.24 
VEGF 1.52 0.21 0.51 0.36 0.20 0.32 >0.99 0.97 >0.99 >0.99 >0.99 >0.99 
COL1α1 15.14 <0.0001 <0.0001 0.0747 <0.0001 0.38 0.03 0.85 0.003 0.002 0.91 <0.0001 
COL1α2 13.09 <0.0001 <0.0001 0.10 <0.0001 0.32 0.04 0.97 0.006 0.006 0.97 0.0009 
ANP 0.61 0.66 0.85 0.59 0.77 0.84 0.99 >0.99 >0.99 >0.99 >0.99 >0.99 
BNP  1.99 0.11 0.62 >0.99 0.16 0.87 0.59 0.90 0.99 0.14 0.86 0.65 
VNP 1.98 0.11 0.99 0.33 0.95 0.15 0.60 >0.99 0.33 0.77 >0.99 0.50 
MR 1.92 0.12 0.94 >0.99 0.59 0.78 0.90 0.95 0.33 0.50 0.85 0.08 
GR1 1.29 0.29 >0.99 0.81 >0.99 0.63 0.69 >0.99 0.49 0.60 >0.99 0.41 
GR 2 0.49 0.74 >0.99 0.74 0.99 0.95 0.80 >0.99 0.97 0.95 0.99 >0.99 
Statistical differences were tested by one-way ANOVA and Tukey HSD Post Hoc tests. F and P statistics (P=overall P-value of 
ANOVA analysis) are shown in the first two columns. P-values from Tukey HSD post-hoc tests are shown for each comparison. 
Significant differences and p-values that boarder to statistical significance (p<0.10) are marked by bold font. PCNA and BNP 
were inversely transformed and SMLC2 log transformed prior to analysis.  
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5.3 List of abbreviations  
ACTH  adrenocorticotropin 
ANP  A-type natriuretic peptide 
BNP   B-type natriuretic peptide 
COL1α1  collagen alpha 1(1) 
COL1α2  collagen alpha 2(1) 
CRH  corticotrophin-releasing hormone  
CSI   cardiosomatic index 
GR1   glucocorticoid receptor 1 
GR2   glucocorticoid receptor 2 
GRE  glucocorticoid responsive element 
HPI-axis hypothalamus-pituitary-interrenal axis 
HR   high responder 
LR   low responder 
MLC  myosin light chain 
MLP   muscle LIM protein 
MR   mineralocorticoid receptor 
mRNA messenger ribonucleic acid  
NFAT   nuclear factor of activated T-cell 
NP  natriuretic peptide 
PCNA  proliferating cell nuclear antigen 
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qRT-PCR  quantitative real-time PCR 
RCAN1  regulator of calcineurin 1 
RIA   Radioimmunoassay 
RIN  RNA integrity number 
SMLC2  slow myosin light chain 2 
VEGF  vascular endothelial growth factor 
VMHC  ventricular myosin heavy chain 
β-MHC  β-myosin heavy chain 
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